## metadata
source file: data/floodlamp/reg/fda-townhalls/f5_fixnames/run_auto/2020-09-16_Virtual Town Hall 26_fixnames.md
last updated: 2025-01-03 Created QA Sections
link pdf: https://www.fda.gov/media/142312/download?attachment
link youtube: https://youtu.be/PfakNcEmaXs
link slides: 
topic: COVID-19


## content

### qa


#### 1. False Positives and Testing Accuracy in SARS-CoV-2 Diagnostics

QA Block 1-1
CLARIFIED QUESTION: How can test developers address concerns related to false positive results for COVID-19 diagnostic tests?
CLARIFIED ANSWER: The FDA collaborates with test developers to investigate and address reported false positives, resolve confirmed issues, and ensure transparency in communicating findings.
VERBATIM QUESTION: How can test developers address concerns related to false positive results for COVID-19 diagnostic tests?
VERBATIM ANSWER: A topic that seems to be well-recognized now and we certainly made some public statements about certain tests is false positives so we are still dealing with some tests that have been publicly mentioned by the FDA and we continue to look for all signals whether they be significant false negatives or false positives and certainly pay a lot of attention to any sort of false results, work with those who are reporting issues as well as the test developers, understand the issues, see if there truly is an issue and if so, to quickly resolve that and quell that. And of course when something is known and decided to make that transparent to all of you, but in general false positives perhaps haven't received as much attention as false negatives but as we move into this pandemic and the response, you know, false positives are important to be aware of.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: False positives, Collaboration with developers, Communication of issues
REVIEW FLAG: False

QA Block 1-2
CLARIFIED QUESTION: What steps should be taken to ensure accurate sensitivity and specificity calculations for tests in low-prevalence populations?
CLARIFIED ANSWER: To ensure accurate test results for low-prevalence populations, it is crucial to understand both the sensitivity and specificity of the tests and to assess their positive predictive value for the specific population being tested.
VERBATIM QUESTION: What steps should be taken to ensure accurate sensitivity and specificity calculations for tests in low-prevalence populations?
VERBATIM ANSWER: It's really important to not only understand the sensitivity and specificity of tests to the best of our ability but it's also important to understand what the positive predictive value for the population in that you're testing.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Sensitivity and specificity in testing, Positive predictive value, Low-prevalence population testing
REVIEW FLAG: False

QA Block 1-3
CLARIFIED QUESTION: How does the positive predictive value (PPV) change with varying population positivity rates when using high-performing tests?
CLARIFIED ANSWER: The positive predictive value (PPV) significantly decreases in low positivity rate populations even with high-performing tests. For instance, a test with 95% sensitivity and 99% specificity in a population with a 0.2% positivity rate yields a PPV of only 16%, meaning one in six positives is truly positive.
VERBATIM QUESTION: How does the positive predictive value (PPV) change with varying population positivity rates when using high-performing tests?
VERBATIM ANSWER: As we've talked about previously a while ago for serology tests even if molecular tests or an antigen test is quite specific and let's just plug-in some numbers into our PPV calculator and so if you plug-in a 95% sensitivity and a 99% specificity against the sensitivity 95 and specificity 99 so many would agree that's a fairly high-performing test. And if you put in a number of perhaps 0.2% positive but again that's 0.2, we have seen that relative level of positivity in a number of different populations who are doing screening or they're doing surveillance, you know, it's interesting because you plug that into a calculator for PPV or positive predictive value it's 1/6 or 16% and that's pretty low. That means that only one out of six positives is an actually true positive result.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Positive predictive value, Population positivity rates, Test performance
REVIEW FLAG: False

QA Block 1-4
CLARIFIED QUESTION: What guidance or tools does the FDA provide for testing positive predictive value in specific populations?
CLARIFIED ANSWER: The FDA provides a Positive Predictive Value (PPV) calculator to assess test performance in specific populations, using sensitivity, specificity, and population positivity rates.
VERBATIM QUESTION: What guidance or tools does the FDA provide for testing positive predictive value in specific populations?
VERBATIM ANSWER: And as we've talked about previously a while ago for serology tests even if molecular tests or an antigen test is quite specific and let's just plug-in some numbers into our PPV calculator and so if you plug-in a 95% sensitivity and a 99% specificity against the sensitivity 95 and specificity 99 so many would agree that's a fairly high-performing test. And if you put in a number of perhaps 0.2% positive but again that's 0.2, we have seen that relative level of positivity in a number of different populations who are doing screening or they're doing surveillance, you know, it's interesting because you plug that into a calculator for PPV or positive predictive value it's 1/6 or 16% and that's pretty low.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Positive Predictive Value, Diagnostic tools, Population-specific testing
REVIEW FLAG: False

QA Block 1-5
CLARIFIED QUESTION: What are the implications of falsely positive results on patient placement in clinical settings, such as COVID-19 wards?
CLARIFIED ANSWER: Falsely positive results can lead to patients being placed in COVID wards where they risk being exposed to infectious individuals. This is especially concerning for at-risk patients, emphasizing the importance of understanding test sensitivity, specificity, and positive predictive value.
VERBATIM QUESTION: What are the implications of falsely positive results on patient placement in clinical settings, such as COVID-19 wards?
VERBATIM ANSWER: We know that in some clinical settings based on a single positive result that patients can be moved into a COVID ward where presumably everybody else has been confirmed positive to have COVID and may carry the virus, may carry infectious levels of the virus, may increase the risk of transmissibility to anyone who goes into that ward and here you'll have a potential patient who is falsely positive, may be in an at-risk group due to the age or previous conditions and goes into that increased-risk ward or area and may unfortunately, you know, contract the disease. So it's really important to not only understand the sensitivity and specificity of tests to the best of our ability but it's also important to understand what the positive predictive value for the population in that you're testing so let's hope that those remarks are helpful.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: False positives, Patient placement risks, Test sensitivity and specificity
REVIEW FLAG: False

QA Block 1-6
CLARIFIED QUESTION: How can developers access and utilize the FDA SARS reference panel data for evaluating their tests?
CLARIFIED ANSWER: The FDA has provided publicly available information on the SARS reference panel, including tables assessing relative LODs for different sample types (e.g., VTM, dry swabs, saliva), organized for ease of understanding. Developers are advised to review these details when interpreting data and making comparisons.
VERBATIM QUESTION: How can developers access and utilize the FDA SARS reference panel data for evaluating their tests?
VERBATIM ANSWER: We assessed relative LODs in three different ways, one for essentially the sample that used or test that uses - sample test that use - VTM and go into an extraction sort of chemistry from a liquid source and then we looked at dry swabs and separately we started looking at saliva. We think that within a sample type, we have three different tables and that's publicly available information. Within a table you can look at relative LOD and you can understand I think to a great degree based on how we ask the testing to be done and our analysis, we have a pretty good rank order, a lower LOD to a higher LOD within a table but making comparisons between tables are a little bit more difficult because the method of assessing the LOD was not exactly the same and we do put some details about how those how the panel was used for the different sample types so that those that go to the table and try to use it understand what those differences may be. So again we hope this publicly-available information on relative LODs will be helpful to the community.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA SARS reference panel, Test evaluation, LOD data
REVIEW FLAG: False

QA Block 1-7
CLARIFIED QUESTION: What distinctions should be noted when comparing limit of detection (LOD) across different sample types like dry swabs, saliva, and VTM?
CLARIFIED ANSWER: The FDA evaluated relative LODs for VTM, dry swabs, and saliva using distinct methods, resulting in separate tables. LOD comparisons within each sample type are reliable, but comparing across sample types is challenging due to differing assessment methods.
VERBATIM QUESTION: What distinctions should be noted when comparing limit of detection (LOD) across different sample types like dry swabs, saliva, and VTM?
VERBATIM ANSWER: We assessed relative LODs in three different ways, one for essentially the sample that used or test that uses - sample test that use - VTM and go into an extraction sort of chemistry from a liquid source and then we looked at dry swabs and separately we started looking at saliva. We think that within a sample type, we have three different tables and that's publicly available information. Within a table you can look at relative LOD and you can understand I think to a great degree based on how we ask the testing to be done and our analysis, we have a pretty good rank order, a lower LOD to a higher LOD within a table but making comparisons between tables are a little bit more difficult because the method of assessing the LOD was not exactly the same and we do put some details about how those how the panel was used for the different sample types so that those that go to the table and try to use it understand what those differences may be.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Limit of detection, Sample types, FDA SARS reference panel
REVIEW FLAG: False

QA Block 1-8
CLARIFIED QUESTION: Are the methods for assessing LOD standardized across all sample types listed in the FDA SARS reference panel?
CLARIFIED ANSWER: The FDA assessed LOD in three different ways for different sample types: VTM with liquid extraction, dry swabs, and saliva. While LOD rankings are consistent within each sample type, comparing LOD across types is challenging due to differing assessment methods.
VERBATIM QUESTION: Are the methods for assessing LOD standardized across all sample types listed in the FDA SARS reference panel?
VERBATIM ANSWER: We assessed relative LODs in three different ways, one for essentially the sample that used or test that uses - sample test that use - VTM and go into an extraction sort of chemistry from a liquid source and then we looked at dry swabs and separately we started looking at saliva. We think that within a sample type, we have three different tables and that's publicly available information. Within a table you can look at relative LOD and you can understand I think to a great degree based on how we ask the testing to be done and our analysis, we have a pretty good rank order, a lower LOD to a higher LOD within a table but making comparisons between tables are a little bit more difficult because the method of assessing the LOD was not exactly the same and we do put some details about how those how the panel was used for the different sample types so that those that go to the table and try to use it understand what those differences may be.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Assessment of LOD, FDA SARS reference panel, Sample types
REVIEW FLAG: False

QA Block 1-9
CLARIFIED QUESTION: When can developers expect the next batch of SARS reference panel results to be posted?
CLARIFIED ANSWER: The FDA is finalizing LOD determinations for additional developers and will post the next batch of SARS reference panel results as soon as they are ready.
VERBATIM QUESTION: When can developers expect the next batch of SARS reference panel results to be posted?
VERBATIM ANSWER: We have contacted a lot more developers in this first batch and so we're already working on finalizing LOD determinations for a lot more and we'll post as soon as we're ready to post the next batch.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: SARS reference panel, Next batch posting timeline
REVIEW FLAG: False


#### 2. Updating Notification Lists and Standard Protocol Practices

QA Block 2-1
CLARIFIED QUESTION: Are you still updating the notification lists on your facts page regularly?
CLARIFIED ANSWER: The FDA is updating the notification lists regularly, although some listings, such as Section A, are voluntary and require permission from the submitter for inclusion.
VERBATIM QUESTION: Are you still updating the notification lists on your facts page regularly?
VERBATIM ANSWER: Yes, we are. I'll double-check on that. I will say that there are some of those, I believe A is voluntary to be listed there so just because somebody has let us know that they validated and may wish to pursue an EUA may at the same time may not give us permission to put it on the notification list but I'll make a note of that to double-check that that is the standard protocol for us to update those notification lists.
SPEAKER QUESTION: Alexis Sauer-Budge
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: notification list updates, EUA process, submission protocol
REVIEW FLAG: False


#### 3. Submitting and Updating EUA for Antigen Tests

QA Block 3-1
CLARIFIED QUESTION: Do we submit one EUA and modify it or do we have to submit two EUAs?
CLARIFIED ANSWER: The decision is up to the submitter. If you have complete data for a sample type and want an earlier EUA authorization, you can submit it and later amend it with additional validations. The FDA allows updates to EUAs and recommends submitting validated data for antigen tests promptly.
VERBATIM QUESTION: Do we submit one EUA and modify it or do we have to submit two EUAs?
VERBATIM ANSWER: So that's totally up to you. I you know, when you have a complete set of data for a particular sample type and you'd like to get you know, an EUA authorization sooner than later, then you may want to submit that before you have all your sample type validations, all the different sample types you want and the validations, the types you want and the validations done. Because we, you know, once an EUA is authorized, we do allow updates to it, right, amendments to it with any changes that would require or new or we recommend new validation. If you've already got some sample types where you definitely met our recommended minimums and the data looks good, then go ahead. I encourage you to go ahead and submit it particularly for antigen tests because we certainly want to have more antigen tests on the market as soon as possible.
SPEAKER QUESTION: Louis Perlmutter
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submission process, Validation for sample types, Antigen tests
REVIEW FLAG: False

QA Block 3-2
CLARIFIED QUESTION: What are the recommended minimum criteria for sample type validation?
CLARIFIED ANSWER: The FDA recommends submitting data that meets its minimum criteria for sample type validation and looks scientifically sound, particularly for antigen tests.
VERBATIM QUESTION: What are the recommended minimum criteria for sample type validation?
VERBATIM ANSWER: If you've already got some sample types where you definitely met our recommended minimums and the data looks good, then go ahead. I encourage you to go ahead and submit it particularly for antigen tests because we certainly want to have more antigen tests on the market as soon as possible.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: validation criteria, sample types, antigen tests
REVIEW FLAG: False

QA Block 3-3
CLARIFIED QUESTION: Can updates or amendments to an EUA be submitted for additional sample types after the initial authorization?
CLARIFIED ANSWER: The FDA allows updates or amendments to an EUA for additional sample types, provided any required new validation is included.
VERBATIM QUESTION: Can updates or amendments to an EUA be submitted for additional sample types after the initial authorization?
VERBATIM ANSWER: Because we, you know, once an EUA is authorized, we do allow updates to it, right, amendments to it with any changes that would require or new or we recommend new validation.
SPEAKER QUESTION: Louis Perlmutter
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA amendments, sample type validation
REVIEW FLAG: False

QA Block 3-4
CLARIFIED QUESTION: Does the FDA prioritize antigen test EUAs to expedite market availability?
CLARIFIED ANSWER: The FDA encourages the submission of antigen tests to increase their market availability as soon as possible.
VERBATIM QUESTION: Does the FDA prioritize antigen test EUAs to expedite market availability?
VERBATIM ANSWER: I encourage you to go ahead and submit it particularly for antigen tests because we certainly want to have more antigen tests on the market as soon as possible.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: antigen test EUAs, FDA prioritization
REVIEW FLAG: False


#### 4. FDA Requirements and Flexibility for At-Home COVID-19 Tests

QA Block 4-1
CLARIFIED QUESTION: What is the standard lab test against which a manufacturer should compare their at-home antigen tests?
CLARIFIED ANSWER: The standard lab test for comparing at-home antigen tests is generally considered to be a high-sensitivity molecular test, as the FDA aims to compare against the best possible standard.
VERBATIM QUESTION: What is the standard lab test against which a manufacturer should compare their at-home antigen tests?
VERBATIM ANSWER: So the question of what is the comparator test is what you're asking, what is the standard lab test and this is typically thought and the outline behind this is a high-sensitivity molecular test. We specify that because we don't want to be comparing something less than the best possible standard and if you go with a less-sensitive test, it may not detect all cases.
SPEAKER QUESTION: Paul Barto
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: standard lab test for comparison, high-sensitivity molecular tests
REVIEW FLAG: False

QA Block 4-2
CLARIFIED QUESTION: Are visually read tests excluded since there isn't a way to automatically report results to a public health agency?
CLARIFIED ANSWER: Visually read tests are not excluded because home tests performed outside of a CLIA lab are not legally required to report results to public health agencies. FDA encourages developers to explore ways to facilitate result reporting to aid the public health response.
VERBATIM QUESTION: Are visually read tests excluded since there isn't a way to automatically report results to a public health agency?
VERBATIM ANSWER: So home tests performed outside of a CLIA lab are not required to report results to the reporting agencies. It's not required by law is my understanding. We do want to stimulate thought about how the tests can be reported in order to aid our public health response to this pandemic so we do in that template ask what are your thoughts about how you can facilitate reporting of results even in a home test situation.
SPEAKER QUESTION: Paul Barto
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Visually read tests, Reporting results, Public health requirements
REVIEW FLAG: False

QA Block 4-3
CLARIFIED QUESTION: Why does the FDA template include a question about reporting test results to public health agencies if it is not a requirement?
CLARIFIED ANSWER: The FDA includes this question in the template to stimulate ideas for reporting home test results to aid pandemic tracking, but it is not a requirement for test authorization.
VERBATIM QUESTION: Why does the FDA template include a question about reporting test results to public health agencies if it is not a requirement?
VERBATIM ANSWER: It is not a requirement. It is not something that we would use to make a decision on whether or not to authorize that test or not. It is a question in the template and that's because we are trying to be a good federal partner and stimulate thought in this area because we think that it's a very responsible thing to do and try to find a way to report these results so that we're tracking the pandemic as best we can.
SPEAKER QUESTION: Paul Barto
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA test result reporting, Public health tracking, Test authorization requirements
REVIEW FLAG: False

QA Block 4-4
CLARIFIED QUESTION: Is it mandatory for at-home COVID-19 tests to have a means to report results to public health agencies for FDA authorization?
CLARIFIED ANSWER: FDA does not require at-home COVID-19 tests to have a means of reporting results to public health agencies for authorization. It is suggested in the template to encourage public health tracking.
VERBATIM QUESTION: Is it mandatory for at-home COVID-19 tests to have a means to report results to public health agencies for FDA authorization?
VERBATIM ANSWER: It is not a requirement. It is not something that we would use to make a decision on whether or not to authorize that test or not. It is a question in the template and that's because we are trying to be a good federal partner and stimulate thought in this area because we think that it's a very responsible thing to do and try to find a way to report these results so that we're tracking the pandemic as best we can.
SPEAKER QUESTION: Paul Barto
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: At-home COVID-19 test requirements, Reporting test results, FDA authorization
REVIEW FLAG: False

QA Block 4-5
CLARIFIED QUESTION: What alternative methods can be used to validate at-home COVID-19 antigen tests if the recommendations in the FDA templates are not followed?
CLARIFIED ANSWER: The FDA is open to alternative methods of validation for at-home COVID-19 antigen tests beyond those recommended in its templates.
VERBATIM QUESTION: What alternative methods can be used to validate at-home COVID-19 antigen tests if the recommendations in the FDA templates are not followed?
VERBATIM ANSWER: There may be alternatives to get to the same place of validation and we're always open to those alternatives. We have given a lot of thought to what the recommendations are in our templates by the time we post them.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation methods, At-home COVID-19 tests, FDA flexibility
REVIEW FLAG: False

QA Block 4-6
CLARIFIED QUESTION: What are the sensitivity requirements for prescription-only at-home COVID-19 antigen tests?
CLARIFIED ANSWER: For prescription-only at-home COVID-19 antigen tests, the FDA recommends a sensitivity of 80%, though it may allow lower sensitivities (70% or more) in serial testing programs.
VERBATIM QUESTION: What are the sensitivity requirements for prescription-only at-home COVID-19 antigen tests?
VERBATIM ANSWER: So I'm going to try to unpack these things one at a time and if I miss some thing, please let me know at the end so you mentioned that at-home test we had the recommended positive agreement or sensitivity of 90%. That is for something that is going to be over-the-counter without prescription. So if there is something that's by-prescription then the recommended PPA or sensitivity is 80% and in fact if you're read Dr. Shuren's and my opinion last week in The Hill, we even suggested something as far as a single test result in the home situation can be as low as 70% perhaps if you had something like a serial test program where instead of just one test result you might have two. You might package two tests and a patient might test themselves on Day 1 and Day 2 or Day 1 and Day 3, whatever the developer, you know, sees as beneficial to increasing that sensitivity.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: sensitivity requirements, at-home COVID-19 tests, prescription-only tests
REVIEW FLAG: False

QA Block 4-7
CLARIFIED QUESTION: Can the sensitivity threshold for over-the-counter at-home tests be reduced if a serial testing approach is implemented?
CLARIFIED ANSWER: The FDA acknowledges that the sensitivity threshold for at-home over-the-counter tests could be reduced to as low as 70% if a serial testing approach is implemented, such as packaging two tests for use on different days to increase accuracy.
VERBATIM QUESTION: Can the sensitivity threshold for over-the-counter at-home tests be reduced if a serial testing approach is implemented?
VERBATIM ANSWER: In fact if you're read Dr. Shuren's and my opinion last week in The Hill, we even suggested something as far as a single test result in the home situation can be as low as 70% perhaps if you had something like a serial test program where instead of just one test result you might have two. You might package two tests and a patient might test themselves on Day 1 and Day 2 or Day 1 and Day 3, whatever the developer, you know, sees as beneficial to increasing that sensitivity.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Sensitivity threshold, Serial testing, At-home tests
REVIEW FLAG: False

QA Block 4-8
CLARIFIED QUESTION: Why has the FDA not received any EUA (Emergency Use Authorization) applications for at-home tests despite publishing guidance?
CLARIFIED ANSWER: The FDA has not received any EUA applications for at-home tests despite having templates available and expressing flexibility.
VERBATIM QUESTION: Why has the FDA not received any EUA (Emergency Use Authorization) applications for at-home tests despite publishing guidance?
VERBATIM ANSWER: I have to say though we haven't received a single EUA application for a home test, not one and we've had our template out there for a long time and we've clearly expressed flexibility so we want to reiterate. We want to see home test submissions and we're willing to be very flexible here.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA applications, At-home tests, FDA guidance
REVIEW FLAG: False

QA Block 4-9
CLARIFIED QUESTION: Is it necessary for rapid antigen or point-of-care molecular tests to demonstrate peak sensitivity during specific symptomatic days (e.g., first five to seven days after symptom onset)?
CLARIFIED ANSWER: FDA emphasizes the importance of evaluating rapid antigen and point-of-care molecular tests for sensitivity during the first five to seven days after symptom onset, as these are the peak days for potential virus transmission.
VERBATIM QUESTION: Is it necessary for rapid antigen or point-of-care molecular tests to demonstrate peak sensitivity during specific symptomatic days (e.g., first five to seven days after symptom onset)?
VERBATIM ANSWER: The other thing to note is that if it's a rapid antigen test or even a point-of-care molecular test, we really are most concerned about the performance of that test that is its sensitivity against you know, a good comparator in those first five to seven days for those who are symptomatic and the first five to seven days after somebody becomes symptomatic. And that's because those are the days that we think and I think there's good literature to support this that that's the peak period of potential ability of those individuals to transfer the virus to somebody else and so we want to definitely identify those people and in the asymptomatic population we want to identify people with similar levels of virus.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Test sensitivity, Symptomatic period, Virus transmission
REVIEW FLAG: False

QA Block 4-10
CLARIFIED QUESTION: How does the FDA evaluate the performance of tests for identifying asymptomatic individuals who may spread the virus?
CLARIFIED ANSWER: The FDA evaluates tests for identifying asymptomatic individuals by focusing on their sensitivity to identify those with transmissible levels of the virus, especially during peak periods for virus spread. They don't rely heavily on LOD since there is no international standard, and the relationship with clinical performance can vary.
VERBATIM QUESTION: How does the FDA evaluate the performance of tests for identifying asymptomatic individuals who may spread the virus?
VERBATIM ANSWER: The other thing to note is that if it's a rapid antigen test or even a point-of-care molecular test, we really are most concerned about the performance of that test that is its sensitivity against you know, a good comparator in those first five to seven days for those who are symptomatic and the first five to seven days after somebody becomes symptomatic. And that's because those are the days that we think and I think there's good literature to support this that that's the peak period of potential ability of those individuals to transfer the virus to somebody else and so we want to definitely identify those people and in the asymptomatic population we want to identify people with similar levels of virus and so we don't look in particular at LOD for a number of reasons. One is there's no international standard so it's really hard to set something that can be applied evenly across all technologies and developers but also it's not always the direct relationship between LOD and clinical performance especially if you want to be sure and identify people who have transmissible levels of virus. You may not need to have the ultimate in sensitivity as far as limited protection goes but you do want to detect those that are most likely to be able to pass-on that virus to somebody else.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: test performance evaluation, asymptomatic transmission, FDA standards
REVIEW FLAG: False

QA Block 4-11
CLARIFIED QUESTION: Why does the FDA avoid using LOD (Limit of Detection) as a primary metric for test validation?
CLARIFIED ANSWER: The FDA does not prioritize LOD as a key validation metric due to the lack of an international standard and its inconsistent correlation with clinical performance, especially for detecting transmissible virus levels critical for public health.
VERBATIM QUESTION: Why does the FDA avoid using LOD (Limit of Detection) as a primary metric for test validation?
VERBATIM ANSWER: We don't look in particular at LOD for a number of reasons. One is there's no international standard so it's really hard to set something that can be applied evenly across all technologies and developers but also it's not always the direct relationship between LOD and clinical performance especially if you want to be sure and identify people who have transmissible levels of virus. You may not need to have the ultimate in sensitivity as far as limited protection goes but you do want to detect those that are most likely to be able to pass-on that virus to somebody else.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Limit of Detection (LOD), FDA test validation, clinical performance
REVIEW FLAG: False

QA Block 4-12
CLARIFIED QUESTION: What are the specific criteria for the FDA to authorize visually-read COVID-19 tests?
CLARIFIED ANSWER: The FDA has authorized only one visually-read test so far, the Abbott BinaxNow, which has shown good performance. The agency is optimistic about more visually-read tests entering the market soon and considers such tests valid diagnostics.
VERBATIM QUESTION: What are the specific criteria for the FDA to authorize visually-read COVID-19 tests?
VERBATIM ANSWER: We haven't authorized, I mean, we've probably authorized just one visually-read test. There is a lot I know in development and hopefully they will come to the market in the relatively near future and there's nothing wrong with the visually-read tests first of all and now the Abbott BinaxNow is a visually-read test and its performance looks good and we look forward to its full availability in the market and the usefulness in this pandemic.
SPEAKER QUESTION: Paul Barto
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA criteria for visually-read tests, Authorization of Abbott BinaxNow, Future visually-read test development
REVIEW FLAG: False

QA Block 4-13
CLARIFIED QUESTION: Is there a difference in how the FDA evaluates visually-read tests compared to other point-of-care tests?
CLARIFIED ANSWER: The FDA has authorized very few visually-read tests but sees no issue with them. The Abbott BinaxNow is an example of a visually-read test with good performance.
VERBATIM QUESTION: Is there a difference in how the FDA evaluates visually-read tests compared to other point-of-care tests?
VERBATIM ANSWER: So we haven't authorized, I mean, we've probably authorized just one visually-read test. There is a lot I know in development and hopefully they will come to the market in the relatively near future and there's nothing wrong with the visually-read tests first of all and now the Abbott BinaxNow is a visually-read test and its performance looks good and we look forward to its full availability in the market and the usefulness in this pandemic.
SPEAKER QUESTION: Paul Barto
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: visually-read tests, FDA evaluation, authorized tests
REVIEW FLAG: False

QA Block 4-14
CLARIFIED QUESTION: How can developers ensure compliance with optional reporting mechanisms suggested in the FDA template for at-home tests?
CLARIFIED ANSWER: Reporting results for home tests outside of a CLIA lab is not legally required, but the FDA encourages developers to explore ways to facilitate reporting to support public health efforts.
VERBATIM QUESTION: How can developers ensure compliance with optional reporting mechanisms suggested in the FDA template for at-home tests?
VERBATIM ANSWER: So home tests performed outside of a CLIA lab are not required to report results to the reporting agencies. It's not required by law is my understanding. We do want to stimulate thought about how the tests can be reported in order to aid our public health response to this pandemic so we do in that template ask what are your thoughts about how you can facilitate reporting of results even in a home test situation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Reporting mechanisms, Home test compliance, FDA templates
REVIEW FLAG: False


#### 5. Asymptomatic Test Validation Challenges and Flexibility in FDA Guidelines

QA Block 5-1
CLARIFIED QUESTION: Are there any studies or results on infectivity level and viral load for symptomatic and asymptomatic individuals that can inform developers?
CLARIFIED ANSWER: Studies show asymptomatic individuals typically have lower viral loads than symptomatic ones, though data varies. Consistent performance evaluation is challenging due to differences in symptom onset and exposure tracking.
VERBATIM QUESTION: Are there any studies or results on infectivity level and viral load for symptomatic and asymptomatic individuals that can inform developers?
VERBATIM ANSWER: Yes, so that is you know, that is the $100,000 question, thank you for asking that. You know, there are a lot of different ways to try to get at that but none are ideal so we have seen variable information in data with regards to if you try to use CTs of a comparator test for giving different populations. We have clearly seen different levels of virus in asymptomatic populations from symptomatic populations, typically lower when there's a difference. Sometimes they don't appear to be different but we don't understand but clearly we see populations where the asymptomatic levels are lower. And you don't have the framework or the guard posts of knowing when somebody's infected unless they had a known exposure that you're then following and tracking them with, you know, because they don't have symptoms so you can't have the same guideposts that we can have for evaluating test performance in symptomatic populations where for example with direct antigen tests, we very specifically ask you to collect in day after symptom onset information as well as day after PCR test results so that we can start to define when is the peak performance days after symptom onset for point of care tests?
SPEAKER QUESTION: Leukner C.N.
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Infectivity levels, Viral load comparisons, Diagnostic test evaluation
REVIEW FLAG: False

QA Block 5-2
CLARIFIED QUESTION: Do you have an estimate of what is clinically relevant in terms of being infectious?
CLARIFIED ANSWER: Determining clinically relevant infectiousness is complex, with variable data showing asymptomatic viral loads are typically lower than symptomatic ones. FDA requires specific validation frameworks for accurate performance insights.
VERBATIM QUESTION: Do you have an estimate of what is clinically relevant in terms of being infectious?
VERBATIM ANSWER: Yes, so that is you know, that is the $100,000 question, thank you for asking that. You know, there are a lot of different ways to try to get at that but none are ideal so we have seen variable information in data with regards to if you try to use CTs of a comparator test for giving different populations. We have clearly seen different levels of virus in asymptomatic populations from symptomatic populations, typically lower when there's a difference. Sometimes they don't appear to be different but we don't understand but clearly we see populations where the asymptomatic levels are lower. And you don't have the framework or the guard posts of knowing when somebody's infected unless they had a known exposure that you're then following and tracking them with, you know, because they don't have symptoms so you can't have the same guideposts that we can have for evaluating test performance in symptomatic populations where for example with direct antigen tests, we very specifically ask you to collect in day after symptom onset information as well as day after PCR test results so that we can start to define when is the peak performance days after symptom onset for point of care tests?
SPEAKER QUESTION: Leukner C.N.
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Clinically relevant infectivity, Asymptomatic vs. symptomatic viral loads, Test validation criteria
REVIEW FLAG: False

QA Block 5-3
CLARIFIED QUESTION: What are the FDA's criteria for evaluating tests for asymptomatic individuals?
CLARIFIED ANSWER: The FDA recommends validation of tests for asymptomatic individuals by using appropriately marked asymptomatic samples, whether banked or from prospective collection. Enrichment studies, such as those from schools or workplaces, are acceptable to efficiently gather samples. The FDA allows flexibility, including enriched pre-market data from asymptomatic individuals and post-market collection to evaluate asymptomatic claims. Matching symptomatic and asymptomatic study populations, particularly by CT values, is encouraged.
VERBATIM QUESTION: What are the FDA's criteria for evaluating tests for asymptomatic individuals?
VERBATIM ANSWER: So here's what we've outlined as what we would like to see as recommended validation of asymptomatic and that is we would like you to collect asymptomatics. Those can be very if you already have a test on the market and people are submitting samples and some of them are clearly marked asymptomatic, we are fine with banked samples. If you have CT results and you look at your population of asymptomatics and, you know, and in the population that your test is looking at, it's appropriate population for whatever claims you're going after and those two populations look very similar and that's also retrospective data but it's also some of that information that we're willing to put, you plan a prospective study. We are allowing enrichment studies so there's lots of schools, workplaces, universities that are doing surveillance and/or screening that are identifying asymptomatic positives and hopefully they're willing to team-up with test developers and so you don't have to do, you can enrich, you know, and find those asymptomatic much more quickly if you can team up with an effort like that and if you can't use the residual sample collected on that individual who's positive, And then you could under the appropriate, you know, consent, we'll say, not that that's necessarily an FDA requirement just you want to do it right due to local-state-federal law you can re-contact that individual, have them come in or go to them or send them a kit and have them retest themselves hopefully within a short period of time after they were positive in their screening or surveillance to add to your asymptomatic population. We do want to see what the molecular results are for that. We also have recently expressed that our interest to even be more flexible on the pre- market, on the pre-authorization side to allow enrichment of asymptomatics so typically if you're adding an asymptomatic claim, it might be 20 patients that we want to see pre-market and now we're saying that if only if it's 20 that we would allow half, 10 of those to be asymptomatic and then add to that with matched symptomatic and a good matching scheme would be to look at people with similar CTs. And then post-market after you've been authorized, complete your prospective collection of asymptomatics. We take that totality of evidence into play so if you have a really great looking test in the symptomatic population and, you know, in those first five to seven days you, you know, you do really well, you know, we're going to take that into account when we look at asymptomatics because clearly in this population where we know that they can pass the virus along and you're doing well, we just want to see is there any differences in sample type that you're using the way you're collecting in an asymptomatic population that brings-up any concerns? So again these are recommendations in our templates.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation criteria, Asymptomatic testing, Test performance
REVIEW FLAG: False

QA Block 5-4
CLARIFIED QUESTION: Can asymptomatic validation involve retrospective or banked samples?
CLARIFIED ANSWER: The FDA allows asymptomatic validation using retrospective or banked samples, provided the samples are appropriately marked and align with the claims being pursued. Enrichment studies are also an option.
VERBATIM QUESTION: Can asymptomatic validation involve retrospective or banked samples?
VERBATIM ANSWER: So here's what we've outlined as what we would like to see as recommended validation of asymptomatic and that is we would like you to collect asymptomatics. Those can be very if you already have a test on the market and people are submitting samples and some of them are clearly marked asymptomatic, we are fine with banked samples. If you have CT results and you look at your population of asymptomatics and, you know, and in the population that your test is looking at, it's appropriate population for whatever claims you're going after and those two populations look very similar and that's also retrospective data but it's also some of that information that we're willing to put, you plan a prospective study. We are allowing enrichment studies so there's lots of schools, workplaces, universities that are doing surveillance and/or screening that are identifying asymptomatic positives and hopefully they're willing to team-up with test developers.
SPEAKER QUESTION: Leukner C.N.
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: asymptomatic validation, retrospective samples, banked samples
REVIEW FLAG: False

QA Block 5-5
CLARIFIED QUESTION: Are enrichment studies an acceptable method for validating asymptomatic testing?
CLARIFIED ANSWER: The FDA allows enrichment studies, where test developers can collaborate with institutions conducting surveillance or screening to quickly identify asymptomatic positives. Under appropriate consent, residual samples can be used or individuals re-contacted for retesting to validate asymptomatic testing.
VERBATIM QUESTION: Are enrichment studies an acceptable method for validating asymptomatic testing?
VERBATIM ANSWER: We are allowing enrichment studies so there's lots of schools, workplaces, universities that are doing surveillance and/or screening that are identifying asymptomatic positives and hopefully they're willing to team-up with test developers and so you don't have to do, you can enrich, you know, and find those asymptomatic much more quickly if you can team up with an effort like that and if you can't use the residual sample collected on that individual who's positive, And then you could under the appropriate, you know, consent, we'll say, not that that's necessarily an FDA requirement just you want to do it right due to local-state-federal law you can re-contact that individual, have them come in or go to them or send them a kit and have them retest themselves hopefully within a short period of time after they were positive in their screening or surveillance to add to your asymptomatic population.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: asymptomatic testing validation, enrichment studies, FDA guidelines
REVIEW FLAG: False

QA Block 5-6
CLARIFIED QUESTION: How should developers handle residual samples collected during screenings or surveillance for asymptomatic validation?
CLARIFIED ANSWER: Developers can collaborate with organizations conducting screenings to identify asymptomatic positives and use residual samples under appropriate consent. They can re-contact individuals to retest after initial positive findings to support validation.
VERBATIM QUESTION: How should developers handle residual samples collected during screenings or surveillance for asymptomatic validation?
VERBATIM ANSWER: We are allowing enrichment studies so there's lots of schools, workplaces, universities that are doing surveillance and/or screening that are identifying asymptomatic positives and hopefully they're willing to team-up with test developers and so you don't have to do, you can enrich, you know, and find those asymptomatic much more quickly if you can team up with an effort like that and if you can't use the residual sample collected on that individual who's positive, And then you could under the appropriate, you know, consent, we'll say, not that that's necessarily an FDA requirement just you want to do it right due to local-state-federal law you can re-contact that individual, have them come in or go to them or send them a kit and have them retest themselves hopefully within a short period of time after they were positive in their screening or surveillance to add to your asymptomatic population.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: asymptomatic validation, residual samples, FDA guidance
REVIEW FLAG: False

QA Block 5-7
CLARIFIED QUESTION: What are the FDA's expectations regarding pre-market and post-market asymptomatic data collection?
CLARIFIED ANSWER: The FDA recommends that asymptomatic data can be collected using banked samples, CT results, or prospective studies. Enrichment studies via schools or workplaces can be used to identify asymptomatic positives. Pre-market requirements allow some patients to be asymptomatic, while post-market involves completing prospective asymptomatic data collection. The FDA considers total evidence and sample type differences.
VERBATIM QUESTION: What are the FDA's expectations regarding pre-market and post-market asymptomatic data collection?
VERBATIM ANSWER: Here's what we've outlined as what we would like to see as recommended validation of asymptomatic and that is we would like you to collect asymptomatics. Those can be very if you already have a test on the market and people are submitting samples and some of them are clearly marked asymptomatic, we are fine with banked samples. If you have CT results and you look at your population of asymptomatics and, you know, and in the population that your test is looking at, it's appropriate population for whatever claims you're going after and those two populations look very similar and that's also retrospective data but it's also some of that information that we're willing to put, you plan a prospective study. We are allowing enrichment studies so there's lots of schools, workplaces, universities that are doing surveillance and/or screening that are identifying asymptomatic positives and hopefully they're willing to team-up with test developers and so you don't have to do, you can enrich, you know, and find those asymptomatic much more quickly if you can team up with an effort like that and if you can't use the residual sample collected on that individual who's positive, And then you could under the appropriate, you know, consent, we'll say, not that that's necessarily an FDA requirement just you want to do it right due to local-state-federal law you can re-contact that individual, have them come in or go to them or send them a kit and have them retest themselves hopefully within a short period of time after they were positive in their screening or surveillance to add to your asymptomatic population. We do want to see what the molecular results are for that. We also have recently expressed that our interest to even be more flexible on the pre- market, on the pre-authorization side to allow enrichment of asymptomatics so typically if you're adding an asymptomatic claim, it might be 20 patients that we want to see pre-market and now we're saying that if only if it's 20 that we would allow half, 10 of those to be asymptomatic and then add to that with matched symptomatic and a good matching scheme would be to look at people with similar CTs. And then post-market after you've been authorized, complete your prospective collection of asymptomatics. We take that totality of evidence into play so if you have a really great looking test in the symptomatic population and, you know, in those first five to seven days you, you know, you do really well, you know, we're going to take that into account when we look at asymptomatics because clearly in this population where we know that they can pass the virus along and you're doing well, we just want to see is there any differences in sample type that you're using the way you're collecting in an asymptomatic population that brings-up any concerns?
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: asymptomatic data collection, FDA validation, pre- and post-market expectations
REVIEW FLAG: False

QA Block 5-8
CLARIFIED QUESTION: Are there specific requirements for matching symptomatic and asymptomatic populations during validation?
CLARIFIED ANSWER: FDA recommends collecting asymptomatic samples for validation, which can include banked samples and enrichment studies. Enrichment, such as collaborating with universities or workplaces conducting surveillance, allows quicker identification of asymptomatic individuals. Tests should match asymptomatic and symptomatic populations with similar CT values. For pre-market claims, at least 10 asymptomatic cases may be evaluated and more data collected post-market as needed.
VERBATIM QUESTION: Are there specific requirements for matching symptomatic and asymptomatic populations during validation?
VERBATIM ANSWER: So here's what we've outlined as what we would like to see as recommended validation of asymptomatic and that is we would like you to collect asymptomatics. Those can be very if you already have a test on the market and people are submitting samples and some of them are clearly marked asymptomatic, we are fine with banked samples. If you have CT results and you look at your population of asymptomatics and, you know, and in the population that your test is looking at, it's appropriate population for whatever claims you're going after and those two populations look very similar and that's also retrospective data but it's also some of that information that we're willing to put, you plan a prospective study. We are allowing enrichment studies so there's lots of schools, workplaces, universities that are doing surveillance and/or screening that are identifying asymptomatic positives and hopefully they're willing to team-up with test developers and so you don't have to do, you can enrich, you know, and find those asymptomatic much more quickly if you can team up with an effort like that and if you can't use the residual sample collected on that individual who's positive, And then you could under the appropriate, you know, consent, we'll say, not that that's necessarily an FDA requirement just you want to do it right due to local-state-federal law you can re-contact that individual, have them come in or go to them or send them a kit and have them retest themselves hopefully within a short period of time after they were positive in their screening or surveillance to add to your asymptomatic population. We do want to see what the molecular results are for that. We also have recently expressed that our interest to even be more flexible on the pre- market, on the pre-authorization side to allow enrichment of asymptomatics so typically if you're adding an asymptomatic claim, it might be 20 patients that we want to see pre-market and now we're saying that if only if it's 20 that we would allow half, 10 of those to be asymptomatic and then add to that with matched symptomatic and a good matching scheme would be to look at people with similar CTs. And then post-market after you've been authorized, complete your prospective collection of asymptomatics.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation requirements, Asymptomatic testing, Matching populations
REVIEW FLAG: False

QA Block 5-9
CLARIFIED QUESTION: What flexibility does the FDA offer for home-use, over-the-counter tests when adding asymptomatic claims?
CLARIFIED ANSWER: The FDA aims to provide flexibility for adding asymptomatic claims and has already authorized some. For non-prescription, home-use, over-the-counter tests, FDA requires understanding performance in symptomatic populations due to the absence of clinician involvement.
VERBATIM QUESTION: What flexibility does the FDA offer for home-use, over-the-counter tests when adding asymptomatic claims?
VERBATIM ANSWER: So what we have attempted to do is provide as much flexibility to add an asymptomatic claim to anybody who wants one. We've clearly authorized some already. We also have the situation that if you're truly non-prescription, home use, over-the-counter, we do want to understand the performance in the symptomatic population because you don't have a clinician involved in selecting, ordering, interpreting a test result in the home situation to any of their patient in evaluating that and knowing okay, you're symptomatic, you're positive or asymptomatic and you're negative, what does that mean versus you want to know if you're carrying the virus and you know, you would really want to know what are the various risk levels?
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA flexibility, Asymptomatic claims, Over-the-counter tests
REVIEW FLAG: False

QA Block 5-10
CLARIFIED QUESTION: How should developers assess the impact of different sample types on test performance in asymptomatic individuals?
CLARIFIED ANSWER: The FDA recommends collecting asymptomatic samples, including using banked or retrospective data, with CT results to compare populations. Developers can team up with surveillance programs to enrich asymptomatic collections. Pre-market, enrichment of asymptomatic samples is allowed, and post-market, a complete prospective collection is required.
VERBATIM QUESTION: How should developers assess the impact of different sample types on test performance in asymptomatic individuals?
VERBATIM ANSWER: So here's what we've outlined as what we would like to see as recommended validation of asymptomatic and that is we would like you to collect asymptomatics. Those can be very if you already have a test on the market and people are submitting samples and some of them are clearly marked asymptomatic, we are fine with banked samples. If you have CT results and you look at your population of asymptomatics and, you know, and in the population that your test is looking at, it's appropriate population for whatever claims you're going after and those two populations look very similar and that's also retrospective data but it's also some of that information that we're willing to put, you plan a prospective study. We are allowing enrichment studies so there's lots of schools, workplaces, universities that are doing surveillance and/or screening that are identifying asymptomatic positives and hopefully they're willing to team-up with test developers and so you don't have to do, you can enrich, you know, and find those asymptomatic much more quickly if you can team up with an effort like that and if you can't use the residual sample collected on that individual who's positive, And then you could under the appropriate, you know, consent, we'll say, not that that's necessarily an FDA requirement just you want to do it right due to local-state-federal law you can re-contact that individual, have them come in or go to them or send them a kit and have them retest themselves hopefully within a short period of time after they were positive in their screening or surveillance to add to your asymptomatic population. We do want to see what the molecular results are for that. We also have recently expressed that our interest to even be more flexible on the pre- market, on the pre-authorization side to allow enrichment of asymptomatics so typically if you're adding an asymptomatic claim, it might be 20 patients that we want to see pre-market and now we're saying that if only if it's 20 that we would allow half, 10 of those to be asymptomatic and then add to that with matched symptomatic and a good matching scheme would be to look at people with similar CTs. And then post-market after you've been authorized, complete your prospective collection of asymptomatics.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation for asymptomatic testing, Use of sample types, Data enrichment methods
REVIEW FLAG: False

QA Block 5-11
CLARIFIED QUESTION: What risk considerations should be accounted for in non-prescription, home-use tests regarding false positives and patient interpretation?
CLARIFIED ANSWER: For non-prescription, home-use tests, FDA highlights the importance of understanding test performance in symptomatic populations due to the absence of clinician interpretation. Knowing the risk levels, such as the likelihood of carrying and transmitting the virus, and minimizing false positives are key concerns.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: And you don't have the framework or the guard posts of knowing when somebody's infected unless they had a known exposure that you're then following and tracking them with, you know, because they don't have symptoms so you can't have the same guideposts that we can have for evaluating test performance in symptomatic populations where for example with direct antigen tests, we very specifically ask you to collect in day after symptom onset information as well as day after PCR test results so that we can start to define when is the peak performance days after symptom onset for point of care tests? So what we have attempted to do is provide as much flexibility to add an asymptomatic claim to anybody who wants one. We've clearly authorized some already. We also have the situation that if you're truly non-prescription, home use, over-the-counter, we do want to understand the performance in the symptomatic population because you don't have a clinician involved in selecting, ordering, interpreting a test result in the home situation to any of their patient in evaluating that and knowing okay, you're symptomatic, you're positive or asymptomatic and you're negative, what does that mean versus you want to know if you're carrying the virus and you know, you would really want to know what are the various risk levels? You know, are you at risk for serious or is somebody in your sphere of influence at risk for you being a carrier? Do you have any episodes in your life that would put you in an increased risk of being a carrier? All those things. As I mentioned earlier on, positive predictive value is also important and you don't want a lot of in the home situation a lot of false positives for a number of reasons.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Non-prescription home-use tests, False positives, Risk considerations
REVIEW FLAG: False


#### 6. Serology Testing Requirements and Sample Timing Guidelines

QA Block 6-1
CLARIFIED QUESTION: Do we need seroconverted samples with longitudinal sampling from the day of detection to a sufficient time point for development of antibodies?
CLARIFIED ANSWER: The FDA does not currently recommend serial testing to track seroconversion timelines in individual patients. They require data related to symptoms or PCR tests and assess test performance by days since symptoms or testing, categorizing results into timeframes like 7-14 days, 14-21 days, etc. They expect strong performance by 21 days.
VERBATIM QUESTION: Do we need seroconverted samples with longitudinal sampling from the day of detection to a sufficient time point for development of antibodies?
VERBATIM ANSWER: That's not a currently recommended study, you know, to serial test patients and determine when they become positive and when they become negative, that is the individual patients. We do ask for data relative to symptoms and/or PCR tests and I would go to the template and look at the recommendations. In that we can, I mean, we've now been authorizing tests and putting it into the EUA summaries or IFUs, you know, by day period and I forget what those are exactly are but obviously we want to know. If we test anything within seven days of symptoms or PCR tests, you know, seven to 14, 14 to 21, greater than 21. I think roughly is what the bins are. You know, even a really good serology test for IGG, you're not going to necessarily have a lot of positivity or as much in those first seven days post- symptoms but we do want to see really good performance say by 21 days, right, so and if your test isn't sufficiently sensitive to detect, you know, a high percentage of antibodies, you know, so if it's IGG, you know, you like to see 90%. We do take-in, you know, we do take into account that a test may ultimately meet that mark after a certain number of days in our authorization.
SPEAKER QUESTION: Jeff Kerriberry
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: seroconversion sample requirements, EUA templates, performance by time after symptoms
REVIEW FLAG: False

QA Block 6-2
CLARIFIED QUESTION: Is it required to have the number of days since diagnosis for a sample when submitting data for serology tests?
CLARIFIED ANSWER: The FDA does not require the number of days since diagnosis for a sample but recommends it. Data on performance is needed to ensure reliable results, particularly between two weeks and two months, as antibody levels may wane over time.
VERBATIM QUESTION: Is it required to have the number of days since diagnosis for a sample when submitting data for serology tests?
VERBATIM ANSWER: Well, the short answer is it depends. It is a recommendation. We'll want to see your data and your line listings to understand performance as best we can but it really protects you the developer to understand this because certainly people can start to lose reactivity. Antibody levels can start to wane after six weeks to eight weeks and then you can start to lose TPA sensitivity or simply because there's been so many days after infection and, you know, in some cases at least the level of antibodies or the detectable antibodies start to go away. And so while we do recommend sort of that peak period that you look at for serology test between two weeks and two months so that you have the best shot of showing that your test is performing well when it should.
SPEAKER QUESTION: Jeff Kerriberry
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology test data requirements, Days since diagnosis, Antibody waning
REVIEW FLAG: False

QA Block 6-3
CLARIFIED QUESTION: What are the specific day ranges the FDA requires test developers to evaluate for serology test performance?
CLARIFIED ANSWER: The FDA advises evaluating test performance in the periods of 0-7 days, 7-14 days, 14-21 days, and over 21 days post-symptoms or PCR testing. Tests should show strong performance by 21 days.
VERBATIM QUESTION: What are the specific day ranges the FDA requires test developers to evaluate for serology test performance?
VERBATIM ANSWER: That's not a currently recommended study, you know, to serial test patients and determine when they become positive and when they become negative, that is the individual patients. We do ask for data relative to symptoms and/or PCR tests and I would go to the template and look at the recommendations. In that we can, I mean, we've now been authorizing tests and putting it into the EUA summaries or IFUs, you know, by day period and I forget what those are exactly are but obviously we want to know. If we test anything within seven days of symptoms or PCR tests, you know, seven to 14, 14 to 21, greater than 21. I think roughly is what the bins are. You know, even a really good serology test for IGG, you're not going to necessarily have a lot of positivity or as much in those first seven days post- symptoms but we do want to see really good performance say by 21 days, right, so and if your test isn't sufficiently sensitive to detect, you know, a high percentage of antibodies, you know, so if it's IGG, you know, you like to see 90%. We do take-in, you know, we do take into account that a test may ultimately meet that mark after a certain number of days in our authorization.
SPEAKER QUESTION: Jeff Kerriberry
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology test performance, FDA guidelines, Day ranges for testing
REVIEW FLAG: False

QA Block 6-4
CLARIFIED QUESTION: How should test developers handle cases where sample collection does not document the number of days since diagnosis?
CLARIFIED ANSWER: Documenting the number of days since diagnosis is recommended for understanding performance, as antibody levels can decrease after six to eight weeks. FDA advises focusing on the peak period between two weeks and two months for reliable test performance.
VERBATIM QUESTION: How should test developers handle cases where sample collection does not document the number of days since diagnosis?
VERBATIM ANSWER: Well, the short answer is it depends. It is a recommendation. We'll want to see your data and your line listings to understand performance as best we can but it really protects you the developer to understand this because certainly people can start to lose reactivity. Antibody levels can start to wane after six weeks to eight weeks and then you can start to lose TPA sensitivity or simply because there's been so many days after infection and, you know, in some cases at least the level of antibodies or the detectable antibodies start to go away. And so while we do recommend sort of that peak period that you look at for serology test between two weeks and two months so that you have the best shot of showing that your test is performing well when it should.
SPEAKER QUESTION: Jeff Kerriberry
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: sample collection, antibody levels, test performance
REVIEW FLAG: False

QA Block 6-5
CLARIFIED QUESTION: What is the role of line listing data in evaluating the performance of serology tests?
CLARIFIED ANSWER: The FDA recommends line listing data to understand performance, as antibody levels may wane over time. This helps ensure tests show good performance during the peak period, which is typically between two weeks and two months after infection.
VERBATIM QUESTION: What is the role of line listing data in evaluating the performance of serology tests?
VERBATIM ANSWER: Well, the short answer is it depends. It is a recommendation. We'll want to see your data and your line listings to understand performance as best we can but it really protects you the developer to understand this because certainly people can start to lose reactivity. Antibody levels can start to wane after six weeks to eight weeks and then you can start to lose TPA sensitivity or simply because there's been so many days after infection and, you know, in some cases at least the level of antibodies or the detectable antibodies start to go away. And so while we do recommend sort of that peak period that you look at for serology test between two weeks and two months so that you have the best shot of showing that your test is performing well when it should.
SPEAKER QUESTION: Jeff Kerriberry
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Line listing data, Serology test performance, Antibody levels
REVIEW FLAG: False

QA Block 6-6
CLARIFIED QUESTION: Does the FDA adjust sensitivity requirements for IGG detection based on the number of days since symptom onset or diagnosis?
CLARIFIED ANSWER: The FDA considers test performance across several timeframes since symptom onset (e.g., within 7 days, 7 to 14 days, 14 to 21 days, and beyond 21 days). Performance at 21 days post-symptom onset is particularly important, and tests should ideally show 90% sensitivity for IGG detection. Sensitivity may be adjusted based on these timeframes.
VERBATIM QUESTION: Does the FDA adjust sensitivity requirements for IGG detection based on the number of days since symptom onset or diagnosis?
VERBATIM ANSWER: In that we can, I mean, we've now been authorizing tests and putting it into the EUA summaries or IFUs, you know, by day period and I forget what those are exactly are but obviously we want to know. If we test anything within seven days of symptoms or PCR tests, you know, seven to 14, 14 to 21, greater than 21. I think roughly is what the bins are. You know, even a really good serology test for IGG, you're not going to necessarily have a lot of positivity or as much in those first seven days post-symptoms but we do want to see really good performance say by 21 days, right, so and if your test isn't sufficiently sensitive to detect, you know, a high percentage of antibodies, you know, so if it's IGG, you know, you like to see 90%. We do take-in, you know, we do take into account that a test may ultimately meet that mark after a certain number of days in our authorization.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: IGG test sensitivity, Symptom onset timelines, Regulatory adjustments
REVIEW FLAG: False

QA Block 6-7
CLARIFIED QUESTION: Are there recommendations for addressing the waning of antibody levels when validating a test's sensitivity?
CLARIFIED ANSWER: The FDA recommends focusing on the peak period of two weeks to two months for serology test validation to maximize performance. Antibody levels tend to wane after six to eight weeks, which can reduce sensitivity.
VERBATIM QUESTION: Are there recommendations for addressing the waning of antibody levels when validating a test's sensitivity?
VERBATIM ANSWER: Well, the short answer is it depends. It is a recommendation. We'll want to see your data and your line listings to understand performance as best we can but it really protects you the developer to understand this because certainly people can start to lose reactivity. Antibody levels can start to wane after six weeks to eight weeks and then you can start to lose TPA sensitivity or simply because there's been so many days after infection and, you know, in some cases at least the level of antibodies or the detectable antibodies start to go away. And so while we do recommend sort of that peak period that you look at for serology test between two weeks and two months so that you have the best shot of showing that your test is performing well when it should.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antibody waning, Test sensitivity, Serology testing recommendations
REVIEW FLAG: False


#### 7. Challenges in Developing SARS-CoV-2 Reference Panels

QA Block 7-3
CLARIFIED QUESTION: Is there any way I can talk to you or someone else to help set up a serology reference panel?
CLARIFIED ANSWER: You can contact the FDA via the same means, and they will connect you with individuals involved in setting up reference panels.
VERBATIM QUESTION: Is there any way I can talk to you or someone else to help set up a serology reference panel?
VERBATIM ANSWER: Yes, you can contact me through the same means and I'll make sure that I connect you with the folks that are, you know, very closely and are involved in setting-up reference panels.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology reference panel, contact process
REVIEW FLAG: False

QA Block 7-4
CLARIFIED QUESTION: If rapid testing is offered to facilities like employers or nursing homes, is it within the limits to use those as a screening test and then perform confirmatory testing for positive results?
CLARIFIED ANSWER: The FDA agrees that confirmatory testing for positive results from rapid screenings is advisable in low positive incidence settings. Ensure compliance with CLIA and CMS regulations for point-of-care testing.
VERBATIM QUESTION: If rapid testing is offered to facilities like employers or nursing homes, is it within the limits to use those as a screening test and then perform confirmatory testing for positive results?
VERBATIM ANSWER: Yes, so you're really talking as I made an intro into today's conversation about a low percent positive situation where you're likely to have even if the test has a fairly high specificity, the chances are greater than none that not that a positive result is a false positive, not because it's necessarily a bad test. It's just that the incidence of positives in that population is so low so doing a confirmatory test in that situation makes absolute sense to me and then I would just, you know, be aware of the CLIA CMS regulations on the certificate, you know, for that testing is, requirements for that testing is being performed with that point of care waived test.
SPEAKER QUESTION: Toby Lowe (FDA IVD Assoc Director)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Rapid testing, Screening and confirmatory testing, CLIA and CMS regulations
REVIEW FLAG: False

QA Block 7-5
CLARIFIED QUESTION: Does a screening test for employers or nursing homes require a lab with a CLIA certificate, whether it's a waiver or otherwise?
CLARIFIED ANSWER: Yes, a screening test requires testing and reporting to be done in a lab with a CLIA certificate, whether it is a waiver or not.
VERBATIM QUESTION: Does a screening test for employers or nursing homes require a lab with a CLIA certificate, whether it's a waiver or otherwise?
VERBATIM ANSWER: If it's clearly been defined as screening, then that testing and the reporting is required to be done in the lab that has the CLIA certificate whether it's waiver or otherwise so I would point to those FAQs on our Website. If those don't answer your questions and you don't know whether you fit into the screening or surveillance, then I would urge you to send us an e-mail at the cdrh-eua- templates@fda.hhs.gov site and with specifics and we'll do our best to give you a very clear answer.
SPEAKER QUESTION: Toby Lowe (FDA IVD Assoc Director)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Screening test requirements, CLIA certificate, Lab certifications
REVIEW FLAG: False

QA Block 7-6
CLARIFIED QUESTION: Is the test being used for screening an FDA-approved rapid test with high sensitivity?
CLARIFIED ANSWER: Yes, the testing scenario described makes sense, especially in a low-positive population where confirmatory testing may be needed due to the likelihood of false positives. CLIA CMS regulations for testing requirements must be adhered to.
VERBATIM QUESTION: Is the test being used for screening an FDA-approved rapid test with high sensitivity?
VERBATIM ANSWER: Yes, so you're really talking as I made an intro into today's conversation about a low percent positive situation where you're likely to have even if the test has a fairly high specificity, the chances are greater than none that not that a positive result is a false positive, not because it's necessarily a bad test. It's just that the incidence of positives in that population is so low so doing a confirmatory test in that situation makes absolute sense to me and then I would just, you know, be aware of the CLIA CMS regulations on the certificate, you know, for that testing is, requirements for that testing is being performed with that point of care waived test.
SPEAKER QUESTION: Toby Lowe (FDA IVD Assoc Director)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: screening tests, FDA-approved rapid test, confirmatory testing
REVIEW FLAG: False

QA Block 7-7
CLARIFIED QUESTION: Does a low percent positive situation increase false positives even for tests with high specificity?
CLARIFIED ANSWER: In a low percent positive situation, false positives are more likely even with highly specific tests due to the low incidence of true positives. Confirmatory testing is appropriate in such cases.
VERBATIM QUESTION: Does a low percent positive situation increase false positives even for tests with high specificity?
VERBATIM ANSWER: Yes, so you're really talking as I made an intro into today's conversation about a low percent positive situation where you're likely to have even if the test has a fairly high specificity, the chances are greater than none that not that a positive result is a false positive, not because it's necessarily a bad test. It's just that the incidence of positives in that population is so low so doing a confirmatory test in that situation makes absolute sense to me and then I would just, you know, be aware of the CLIA CMS regulations on the certificate, you know, for that testing is, requirements for that testing is being performed with that point of care waived test.
SPEAKER QUESTION: Toby Lowe (FDA IVD Assoc Director)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: False positives, Low prevalence scenarios, Confirmatory testing
REVIEW FLAG: False

QA Block 7-8
CLARIFIED QUESTION: What are the CLIA CMS regulations regarding certificates and requirements for point-of-care waived testing?
CLARIFIED ANSWER: According to the FDA, point-of-care waived testing must comply with CLIA CMS regulations regarding necessary certificates and requirements for the testing being performed.
VERBATIM QUESTION: What are the CLIA CMS regulations regarding certificates and requirements for point-of-care waived testing?
VERBATIM ANSWER: Yes, so you're really talking as I made an intro into today's conversation about a low percent positive situation where you're likely to have even if the test has a fairly high specificity, the chances are greater than none that not that a positive result is a false positive, not because it's necessarily a bad test. It's just that the incidence of positives in that population is so low so doing a confirmatory test in that situation makes absolute sense to me and then I would just, you know, be aware of the CLIA CMS regulations on the certificate, you know, for that testing is, requirements for that testing is being performed with that point of care waived test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CLIA CMS regulations, point-of-care testing, testing requirements
REVIEW FLAG: False

QA Block 7-9
CLARIFIED QUESTION: What are the quality control and validation steps performed by the FDA to ensure consistency between reference panels for different SARS-CoV-2 tests?
CLARIFIED ANSWER: The FDA, in collaboration with NCI and federal partners, runs extensive quality control to ensure consistency between reference panels, including QC testing of samples, verifying their history, and matching performance expectations across panels despite limited resources.
VERBATIM QUESTION: What are the quality control and validation steps performed by the FDA to ensure consistency between reference panels for different SARS-CoV-2 tests?
VERBATIM ANSWER: Sure, those are absolutely great questions, we still have a very active program at NCI, our federal partners in the FDA are still testing kits that have been sent to NCI and we're moving into our third panel and are already planning the fourth panel. It has been a lot of work, doable, but a lot of work to source the samples that have sufficient volumes to create these panels at NCI, to properly vet them with the various QC testing that we do and making sure that we know their history and that we are doing the very best job that's possible to match Panel 1, Panel 2, Panel 3, Panel 4 with regard to the types and samples, the titer of the samples so that we can as best as we possible with the limited resources on some of these samples match performance expectations between the panels.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Quality control for reference panels, Validation processes, Consistency in SARS-CoV-2 tests
REVIEW FLAG: False


#### 8. Dr. Sara Brenner's Role and Contact Information

QA Block 8-1
CLARIFIED QUESTION: Could you refresh me on the name of the individual focused on software applications, data analytics, and data collection algorithms, and how she can be contacted?
CLARIFIED ANSWER: Dr. Sara Brenner, Chief Medical Officer for the IVD Office at the FDA, is currently on a detail with the HHS testing task force. She can be contacted via the cdrh-eua-templates@fda.hhs.gov email address.
VERBATIM QUESTION: Could you refresh me on the name of the individual focused on software applications, data analytics, and data collection algorithms, and how she can be contacted?
VERBATIM ANSWER: Yes, Dr. Sara Brenner. She is the Chief Medical Officer for the IVD Office at the FDA. She is currently on a detail, we say, to the testing task force, an HHS task force in HHS focused on data analytics. She would typically would be on these calls but when she started that detail, this time period overlapped this call. The time that she was involved with the task force overlapped this call so she could no longer participate in this particular call. Well if she joins me on CDC calls routinely and APHL calls on a weekly basis or on an every-other-week basis for those calls but again Sara Brenner and you can reach out to her through the cdrh-eua-templates@fda.hhs.gov e- mail and the team that receive those e-mails will put you in contact with her.
SPEAKER QUESTION: Jonathan Cohen
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA contact, software applications, data analytics
REVIEW FLAG: False


#### 9. Antigen Test Validation and Point-of-Care Study Guidelines

QA Block 9-1
CLARIFIED QUESTION: Are there updates or specific recommendations in the antigen test template regarding point-of-care (POC) equivalent CLIA waiver studies for an EUA?
CLARIFIED ANSWER: The antigen test template has been updated to include recommendations for point-of-care equivalent CLIA waiver studies for an EUA. These studies, including user studies, are detailed in the template available on the FDA's in vitro diagnostic EUA website.
VERBATIM QUESTION: Are there updates or specific recommendations in the antigen test template regarding point-of-care (POC) equivalent CLIA waiver studies for an EUA?
VERBATIM ANSWER: Yes, so first is we did at least update the antigen template to have point of care equivalent of CLIA waiver recommendations for an EUA and so those studies including user studies are in the template now so I would refer you to that template which is posted on our the Website for this is the in vitro diagnostic EUAs FDA Website and we have all our templates listed there and that would be the antigen template.
SPEAKER QUESTION: Jessica Wasserman
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen test template updates, Point-of-care CLIA waiver recommendations, EUA studies
REVIEW FLAG: False

QA Block 9-2
CLARIFIED QUESTION: Is it correct that the antigen test template suggests validating with 30 positive and 30 negative samples, and that the inclusion of asymptomatic claims is left to the developer's discretion?
CLARIFIED ANSWER: The FDA requires data to validate asymptomatic claims, which will be included in the EUA summary or instructions for use if provided by developers.
VERBATIM QUESTION: Is it correct that the antigen test template suggests validating with 30 positive and 30 negative samples, and that the inclusion of asymptomatic claims is left to the developer's discretion?
VERBATIM ANSWER: If a test developer wants specifically to say that our test is validated for asymptomatic individual, then we want to see the data for that and we want to be able to post the validation data in the EUA summary or IFU so
SPEAKER QUESTION: Jessica Wasserman
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen test validation, Asymptomatic claims, FDA EUA requirements
REVIEW FLAG: False

QA Block 9-3
CLARIFIED QUESTION: Can test developers mix prospective patient samples with banked samples for POC studies to expedite market access for new antigen tests?
CLARIFIED ANSWER: The FDA allows developers to mix prospective patient samples with banked samples for POC studies to expedite market access for new antigen tests. A post-authorization commitment is required to complete prospective studies.
VERBATIM QUESTION: Can test developers mix prospective patient samples with banked samples for POC studies to expedite market access for new antigen tests?
VERBATIM ANSWER: While point-of-care tests, we really want to see how it performs prospectively in the point-of-care setting. In order to speed access to point-of-care tests that haven't been previously cleared or authorized for other antigens not SARS and to get these new tests that haven't been seen before by the Agency on the market, we are allowing for you to supplement prospective patients in the point-of-care with banked samples that work with you and your technology. There is going to be a post-market, post-authorization commitment to complete the prospective portions of the point-of-care studies and there are certain ways that we want you to, you know, add those banked samples into the testing that's done in a point-of-care setting for the authorization.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: POC validation, Sample mixing, Antigen tests
REVIEW FLAG: False

QA Block 9-4
CLARIFIED QUESTION: What is the FDA's stance on post-market commitments for completing prospective portions of POC studies?
CLARIFIED ANSWER: FDA requires a post-market commitment to complete prospective portions of point-of-care studies, with guidance on integrating banked samples into POC testing for authorization.
VERBATIM QUESTION: What is the FDA's stance on post-market commitments for completing prospective portions of POC studies?
VERBATIM ANSWER: There is going to be a post-market, post-authorization commitment to complete the prospective portions of the point-of-care studies and there are certain ways that we want you to, you know, add those banked samples into the testing that's done in a point-of-care setting for the authorization.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: post-market commitment, POC studies, banked sample integration
REVIEW FLAG: False

QA Block 9-5
CLARIFIED QUESTION: What should test developers provide if they wish to validate their test specifically for asymptomatic individuals?
CLARIFIED ANSWER: Test developers must provide validation data for asymptomatic individuals, which will be posted in the EUA summary or IFU.
VERBATIM QUESTION: What should test developers provide if they wish to validate their test specifically for asymptomatic individuals?
VERBATIM ANSWER: If a test developer wants specifically to say that our test is validated for asymptomatic individual, then we want to see the data for that and we want to be able to post the validation data in the EUA summary or IFU.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: asymptomatic validation, EUA submission requirements
REVIEW FLAG: False

QA Block 9-6
CLARIFIED QUESTION: Did all antigen tests that received CLIA waivers submit POC data similar to the molecular template?
CLARIFIED ANSWER: Antigen tests that received CLIA waivers interacted with the FDA team, which provided feedback on point-of-care validation, and further guidance can be obtained through email.
VERBATIM QUESTION: Did all antigen tests that received CLIA waivers submit POC data similar to the molecular template?
VERBATIM ANSWER: Well, they interacted with our team and our team gave them feedback so the team, now if you send in an e-mail, usually through a pre-EUA request, they can now give you the feedback on what to do for point of care. What do we recommend that our current thinking is for point-of-care validation. I've given them authorization to go ahead and give you an e-mail response which should happen very quickly after you send an e-mail to our template's e-mail address.
SPEAKER QUESTION: Jessica Wasserman
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CLIA waiver, antigen test validation, POC data
REVIEW FLAG: False

QA Block 9-7
CLARIFIED QUESTION: What is the process for receiving current FDA feedback on point-of-care validation for antigen tests?
CLARIFIED ANSWER: To receive feedback on point-of-care validation for antigen tests, submit an email, usually via a pre-EUA request, to the FDA's template email address. The FDA's team is authorized to provide a response quickly.
VERBATIM QUESTION: What is the process for receiving current FDA feedback on point-of-care validation for antigen tests?
VERBATIM ANSWER: Well, they interacted with our team and our team gave them feedback so the team, now if you send in an e-mail, usually through a pre-EUA request, they can now give you the feedback on what to do for point of care. What do we recommend that our current thinking is for point-of-care validation. I've given them authorization to go ahead and give you an e-mail response which should happen very quickly after you send an e-mail to our template's e-mail address.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Point-of-care validation, FDA feedback, Antigen tests
REVIEW FLAG: False

QA Block 9-8
CLARIFIED QUESTION: Does the updated version of the antigen test template include specific recommendations for validating point-of-care (POC) tests?
CLARIFIED ANSWER: The updated antigen test template includes CLIA waiver recommendations for point-of-care tests in EUA applications, and these studies, including user studies, are detailed in the template available on the FDA's in vitro diagnostic EUA website.
VERBATIM QUESTION: Does the updated version of the antigen test template include specific recommendations for validating point-of-care (POC) tests?
VERBATIM ANSWER: Yes, so first is we did at least update the antigen template to have point of care equivalent of CLIA waiver recommendations for an EUA and so those studies including user studies are in the template now so I would refer you to that template which is posted on our the Website for this is the in vitro diagnostic EUAs FDA Website and we have all our templates listed there and that would be the antigen template.
SPEAKER QUESTION: Jessica Wasserman
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen test template, POC test validation, CLIA waiver
REVIEW FLAG: False

QA Block 9-9
CLARIFIED QUESTION: What guidelines should developers follow for incorporating banked samples into POC validation studies for EUA authorization?
CLARIFIED ANSWER: FDA permits supplementing prospective POC validation studies with banked samples compatible with the test technology to expedite EUA authorization. Developers must complete prospective studies post-authorization.
VERBATIM QUESTION: What guidelines should developers follow for incorporating banked samples into POC validation studies for EUA authorization?
VERBATIM ANSWER: ...while point-of-care tests, we really want to see how it performs prospectively in the point-of-care setting. In order to speed access to point-of-care tests that haven't been previously cleared or authorized for other antigens not SARS and to get these new tests that haven't been seen before by the Agency on the market, we are allowing for you to supplement prospective patients in the point-of-care with banked samples that work with you and your technology. There is going to be a post-market, post-authorization commitment to complete the prospective portions of the point-of-care studies and there are certain ways that we want you to, you know, add those banked samples into the testing that's done in a point-of-care setting for the authorization...
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: POC validation studies, Banked samples, EUA guidelines
REVIEW FLAG: False

QA Block 9-11
CLARIFIED QUESTION: What is the FDA's position on the use of tests for asymptomatic individuals without a specific claim on the label?
CLARIFIED ANSWER: The FDA allows off-label use of tests for asymptomatic individuals, even if there isn't a specific claim for that purpose. Physicians are encouraged to test and report results. Developers seeking a formal claim must provide validation data for FDA review.
VERBATIM QUESTION: What is the FDA's position on the use of tests for asymptomatic individuals without a specific claim on the label?
VERBATIM ANSWER: and then with asymptomatic we have very clearly stated in our Website that physicians can, clinicians who place orders for tests, can place an off-label order for a test to be used in an asymptomatic individual even though there isn't a claim for that particular test and we are encouraging those that are using those tests to perform the test on those individuals and report-out those results. If a test developer wants specifically to say that our test is validated for asymptomatic individual, then we want to see the data for that and we want to be able to post the validation data in the EUA summary or IFU so
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Asymptomatic testing, Off-label use, Validation for claims
REVIEW FLAG: False

QA Block 9-12
CLARIFIED QUESTION: What data must be included if a developer wants to validate an antigen test for use in asymptomatic individuals?
CLARIFIED ANSWER: Developers must provide data validating the test for asymptomatic individuals, which will be included in the EUA summary or IFU.
VERBATIM QUESTION: What data must be included if a developer wants to validate an antigen test for use in asymptomatic individuals?
VERBATIM ANSWER: If a test developer wants specifically to say that our test is validated for asymptomatic individual, then we want to see the data for that and we want to be able to post the validation data in the EUA summary or IFU.
SPEAKER QUESTION: Jessica Wasserman
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen test validation, Asymptomatic individuals, EUA data requirements
REVIEW FLAG: False

QA Block 9-13
CLARIFIED QUESTION: Where can developers find the most current version of the antigen test template?
CLARIFIED ANSWER: Developers can find the most current version of the antigen test template on the FDA's in vitro diagnostic EUAs website, where all templates are listed.
VERBATIM QUESTION: Where can developers find the most current version of the antigen test template?
VERBATIM ANSWER: I would refer you to that template which is posted on our the Website for this is the in vitro diagnostic EUAs FDA Website and we have all our templates listed there and that would be the antigen template.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen test template, FDA EUA website
REVIEW FLAG: False


#### 10. Home-Based Testing for HPV, Pap, and SARS-CoV-2

QA Block 10-1
CLARIFIED QUESTION: Has anyone tried to test vaginal fluids for home test self-collection together with HPV and pap tests for a combined diagnostic model including COVID-19, HPV, and pap tests?
CLARIFIED ANSWER: FDA has not authorized combined SARS-CoV-2 and PAP testing with vaginal fluids; validation would require extensive PMA-level approval. FDA encourages developers with supporting data to engage in discussions, and alternatives like saliva testing are already authorized for home self-collection.
VERBATIM QUESTION: Has anyone tried to test vaginal fluids for home test self-collection together with HPV and pap tests for a combined diagnostic model including COVID-19, HPV, and pap tests?
VERBATIM ANSWER: So you want to combine SARS and PAP testing into one? It's not something that we've authorized and it certainly isn't a common respiratory virus sample type, vaginal fluid, you know, in general if you have data to support that sample type, we can't really argue with data. Just realize that each PD testing, molecular testing is a PMA-level authorization in the U.S. and that is quite an extensive validation so that would certainly you know, entail a lot of discussion. The other thing is depending on the actual test type, we've authorized quite a few saliva sample types for testing and that is certainly something that's very readily available. And easily collected at home and doesn't require swabs, doesn't require, you know, VTM which can be in short supply, and obviously we've authorized patient self-collection at home with proper validation of of saliva test so again, we're open to what developers develop. There are certain practical pathways that might be easier for a test developer than others. Always open and especially if there's data. I just want to give you a couple of my thoughts there.
SPEAKER QUESTION: Bolivar Markovich
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: vaginal fluid testing, home test self-collection, PMA-level authorization
REVIEW FLAG: False

QA Block 10-2
CLARIFIED QUESTION: What types of data are required to support the use of non-traditional sample types, like vaginal fluid, for COVID-19 testing?
CLARIFIED ANSWER: FDA requires supporting data for validating non-traditional sample types like vaginal fluid. Molecular testing involves extensive PMA-level authorization.
VERBATIM QUESTION: What types of data are required to support the use of non-traditional sample types, like vaginal fluid, for COVID-19 testing?
VERBATIM ANSWER: It's not something that we've authorized and it certainly isn't a common respiratory virus sample type, vaginal fluid, you know, in general if you have data to support that sample type, we can't really argue with data. Just realize that each PD testing, molecular testing is a PMA-level authorization in the U.S. and that is quite an extensive validation so that would certainly you know, entail a lot of discussion.
SPEAKER QUESTION: Bolivar Markovich
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: non-traditional sample types, vaginal fluid testing, data requirements
REVIEW FLAG: False

QA Block 10-3
CLARIFIED QUESTION: Why is molecular testing considered a PMA-level authorization, and what does this involve?
CLARIFIED ANSWER: Molecular testing, including each PD test, is considered a PMA-level authorization in the U.S., requiring extensive validation and significant discussion with the FDA.
VERBATIM QUESTION: Why is molecular testing considered a PMA-level authorization, and what does this involve?
VERBATIM ANSWER: Just realize that each PD testing, molecular testing is a PMA-level authorization in the U.S. and that is quite an extensive validation so that would certainly you know, entail a lot of discussion.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Molecular testing, PMA-level authorization, Validation requirements
REVIEW FLAG: False

QA Block 10-4
CLARIFIED QUESTION: What are the benefits and challenges of using saliva as a sample type for COVID-19 diagnostic testing?
CLARIFIED ANSWER: FDA has authorized several saliva sample types for COVID-19 testing. Saliva is easy to collect at home, does not require swabs or VTM, and is readily available. Test developers have pathways for validation, but challenges depend on the specific test type.
VERBATIM QUESTION: What are the benefits and challenges of using saliva as a sample type for COVID-19 diagnostic testing?
VERBATIM ANSWER: The other thing is depending on the actual test type, we've authorized quite a few saliva sample types for testing and that is certainly something that's very readily available. And easily collected at home and doesn't require swabs, doesn't require, you know, VTM which can be in short supply, and obviously we've authorized patient self-collection at home with proper validation of of saliva test so again, we're open to what developers develop. There are certain practical pathways that might be easier for a test developer than others.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva sample type, COVID-19 diagnostics, home testing
REVIEW FLAG: False

QA Block 10-5
CLARIFIED QUESTION: Are there specific pathways or processes that the FDA considers easier for test developers based on the type of diagnostic test?
CLARIFIED ANSWER: The FDA indicates that some practical pathways may be easier for test developers, especially if supported by data.
VERBATIM QUESTION: Are there specific pathways or processes that the FDA considers easier for test developers based on the type of diagnostic test?
VERBATIM ANSWER: There are certain practical pathways that might be easier for a test developer than others. Always open and especially if there's data.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA diagnostic test pathways, Easier pathways for test development
REVIEW FLAG: False

### removed qa blocks
QA Block 1-10
CLARIFIED QUESTION: What are the specific details about the methods used in assessing LOD for the FDA SARS reference panel?
CLARIFIED ANSWER: FDA assessed LODs for the SARS reference panel using three methods: testing samples with VTM and liquid extraction chemistry, dry swabs, and saliva. Results are in publicly available tables ranked by LOD within each sample type, though comparing across tables is challenging due to differing methodologies.
VERBATIM QUESTION: What are the specific details about the methods used in assessing LOD for the FDA SARS reference panel?
VERBATIM ANSWER: We assessed relative LODs in three different ways, one for essentially the sample that used or test that uses - sample test that use - VTM and go into an extraction sort of chemistry from a liquid source and then we looked at dry swabs and separately we started looking at saliva. We think that within a sample type, we have three different tables and that's publicly available information. Within a table you can look at relative LOD and you can understand I think to a great degree based on how we ask the testing to be done and our analysis, we have a pretty good rank order, a lower LOD to a higher LOD within a table but making comparisons between tables are a little bit more difficult because the method of assessing the LOD was not exactly the same and we do put some details about how those how the panel was used for the different sample types so that those that go to the table and try to use it understand what those differences may be.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: LOD methods, FDA SARS reference panel, Sample type analysis
REVIEW FLAG: False

QA Block 7-1
CLARIFIED QUESTION: Do you have any plans for providing a reference panel for antigen test developers?
CLARIFIED ANSWER: FDA is actively discussing and working towards establishing reference panels for antigen tests, but sourcing challenges make it difficult to achieve widely available panels. Efforts with international standards are ongoing.
VERBATIM QUESTION: Do you have any plans for providing a reference panel for antigen test developers?
VERBATIM ANSWER: Sure, those are absolutely great questions, we still have a very active program at NCI, our federal partners in the FDA are still testing kits that have been sent to NCI and we're moving into our third panel and are already planning the fourth panel. It has been a lot of work, doable, but a lot of work to source the samples that have sufficient volumes to create these panels at NCI, to properly vet them with the various QC testing that we do and making sure that we know their history and that we are doing the very best job that's possible to match Panel 1, Panel 2, Panel 3, Panel 4 with regard to the types and samples, the titer of the samples so that we can as best as we possible with the limited resources on some of these samples match performance expectations between the panels. So a ton of work goes into this and it would be phenomenal if we had enough samples and sample volumes to be able to do this for serology. It is quite challenging to source those samples in that kind of situation to make it widely available. It's always been a goal and it's talked about frequently within our federal partner team and anyways, they're just some real challenges in getting those samples. They're not unlimited so with the FDA reference panel that went out starting in May, after it was developed, we grew up at the FDA virus and we then inactivated, we tested that it was inactivated, and we created the panel but that is a renewable resource through culture. On the antigen side, we've definitely had this conversation with our federal partners. It is definitely something that would be ideal to have as well. It also has its challenges so we essentially you know, to do this well and we've had a program that CDC has led for a number of years relative to flu where they make an annual proficiency test panel available for various key strains of flu for primarily for rapid antigen tests but molecular tests have also been very active in using those panels to surveil. You know, flu, when you grow a virus and you create these panels, there's less perhaps concern about this as a biological agent, flu relative to SARS so there are additional considerations for SARS but it's definitely been on the plate for conversation. The other thing that I did want to follow-up isn't really a question about are these international standards. The reference panel that we sent out, as soon as the international standard for molecular is available and we're looking at potentially year-end, we will anchor the FDA reference panel to that and we'll be able to translate the results like we've posted to international in units. We think that will be a huge advance and on top of what we've already done. Similarly the international community is working on international standards for antigen tests and serology tests and so we're obviously monitoring and interact at table and doing what we can to assist in that development work and can be ready to implement the two worlds that become available when we do have some available so long-winded answer, great question, would be tremendous resources and all I can say is that we're doing our best to work on it right now.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen reference panels, Sample sourcing challenges, International standards
REVIEW FLAG: False

QA Block 7-2
CLARIFIED QUESTION: Do you have any plans for providing a reference panel for serology test developers?
CLARIFIED ANSWER: FDA is working on creating consistent reference panels for serology and antigen tests, but challenges such as sourcing sufficient sample volumes and managing biological agent concerns make it difficult. International standards are being developed as well.
VERBATIM QUESTION: Do you have any plans for providing a reference panel for serology test developers?
VERBATIM ANSWER: Sure, those are absolutely great questions, we still have a very active program at NCI, our federal partners in the FDA are still testing kits that have been sent to NCI and we're moving into our third panel and are already planning the fourth panel. It has been a lot of work, doable, but a lot of work to source the samples that have sufficient volumes to create these panels at NCI, to properly vet them with the various QC testing that we do and making sure that we know their history and that we are doing the very best job that's possible to match Panel 1, Panel 2, Panel 3, Panel 4 with regard to the types and samples, the titer of the samples so that we can as best as we possible with the limited resources on some of these samples match performance expectations between the panels. So a ton of work goes into this and it would be phenomenal if we had enough samples and sample volumes to be able to do this for serology. It is quite challenging to source those samples in that kind of situation to make it widely available. It's always been a goal and it's talked about frequently within our federal partner team and anyways, they're just some real challenges in getting those samples. They're not unlimited so with the FDA reference panel that went out starting in May, after it was developed, we grew up at the FDA virus and we then inactivated, we tested that it was inactivated, and we created the panel but that is a renewable resource through culture. On the antigen side, we've definitely had this conversation with our federal partners. It is definitely something that would be ideal to have as well. It also has its challenges so we essentially you know, to do this well and we've had a program that CDC has led for a number of years relative to flu where they make an annual proficiency test panel available for various key strains of flu for primarily for rapid antigen tests but molecular tests have also been very active in using those panels to surveil. You know, flu, when you grow a virus and you create these panels, there's less perhaps concern about this as a biological agent, flu relative to SARS so there are additional considerations for SARS but it's definitely been on the plate for conversation. The other thing that I did want to follow-up isn't really a question about are these international standards. The reference panel that we sent out, as soon as the international standard for molecular is available and we're looking at potentially year-end, we will anchor the FDA reference panel to that and we'll be able to translate the results like we've posted to international in units. We think that will be a huge advance and on top of what we've already done. Similarly the international community is working on international standards for antigen tests and serology tests and so we're obviously monitoring and interact at table and doing what we can to assist in that development work and can be ready to implement the two worlds that become available when we do have some available so long-winded answer, great question, would be tremendous resources and all I can say is that we're doing our best to work on it right now.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Reference panels, Serology test development, Challenges with sample sourcing
REVIEW FLAG: False

QA Block 7-10
CLARIFIED QUESTION: What challenges does the FDA face in sourcing biological samples for developing reference panels for serology and antigen tests?
CLARIFIED ANSWER: Sourcing sufficient sample volumes for reference panels is highly challenging due to limited availability, the need for detailed quality control, and ensuring proper sample history. While virus culture provides a renewable resource, creating such panels remains complex and resource-intensive.
VERBATIM QUESTION: What challenges does the FDA face in sourcing biological samples for developing reference panels for serology and antigen tests?
VERBATIM ANSWER: It has been a lot of work, doable, but a lot of work to source the samples that have sufficient volumes to create these panels at NCI, to properly vet them with the various QC testing that we do and making sure that we know their history and that we are doing the very best job that's possible to match Panel 1, Panel 2, Panel 3, Panel 4 with regard to the types and samples, the titer of the samples so that we can as best as we possible with the limited resources on some of these samples match performance expectations between the panels. So a ton of work goes into this and it would be phenomenal if we had enough samples and sample volumes to be able to do this for serology. It is quite challenging to source those samples in that kind of situation to make it widely available. It's always been a goal and it's talked about frequently within our federal partner team and anyways, they're just some real challenges in getting those samples. They're not unlimited so with the FDA reference panel that went out starting in May, after it was developed, we grew up at the FDA virus and we then inactivated, we tested that it was inactivated, and we created the panel but that is a renewable resource through culture.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Challenges sourcing biological samples, Reference panels for serology tests, FDA sample quality control
REVIEW FLAG: False

QA Block 7-11
CLARIFIED QUESTION: Is there a renewable method for creating reference panels for serology and antigen tests similar to the inactivation and growth process used for the molecular test reference panel?
CLARIFIED ANSWER: The FDA has a renewable method for molecular test reference panels through virus culture and inactivation. For antigen panels, similar efforts are ongoing but face challenges, including sample sourcing and concerns related to SARS as a biological agent.
VERBATIM QUESTION: Is there a renewable method for creating reference panels for serology and antigen tests similar to the inactivation and growth process used for the molecular test reference panel?
VERBATIM ANSWER: With the FDA reference panel that went out starting in May, after it was developed, we grew up at the FDA virus and we then inactivated, we tested that it was inactivated, and we created the panel but that is a renewable resource through culture. On the antigen side, we've definitely had this conversation with our federal partners. It is definitely something that would be ideal to have as well. It also has its challenges so we essentially you know, to do this well and we've had a program that CDC has led for a number of years relative to flu where they make an annual proficiency test panel available for various key strains of flu for primarily for rapid antigen tests but molecular tests have also been very active in using those panels to surveil. You know, flu, when you grow a virus and you create these panels, there's less perhaps concern about this as a biological agent, flu relative to SARS so there are additional considerations for SARS but it's definitely been on the plate for conversation.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: reference panels, serology and antigen tests, renewable methods
REVIEW FLAG: False

QA Block 7-12
CLARIFIED QUESTION: Can antigen test developers utilize international standards when they become available, and how will these interact with existing FDA reference panels?
CLARIFIED ANSWER: FDA intends to anchor its reference panel to international standards for molecular, antigen, and serology tests once these standards are available. This will allow converting results into international units and improve their utility.
VERBATIM QUESTION: Can antigen test developers utilize international standards when they become available, and how will these interact with existing FDA reference panels?
VERBATIM ANSWER: The reference panel that we sent out, as soon as the international standard for molecular is available and we're looking at potentially year-end, we will anchor the FDA reference panel to that and we'll be able to translate the results like we've posted to international in units. We think that will be a huge advance and on top of what we've already done. Similarly the international community is working on international standards for antigen tests and serology tests and so we're obviously monitoring and interact at table and doing what we can to assist in that development work and can be ready to implement the two worlds that become available when we do have some available.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: International standards, Antigen test reference panels, FDA reference panel integration
REVIEW FLAG: False

QA Block 7-13
CLARIFIED QUESTION: What role does the CDC proficiency test panel program for flu play in the framework or development of SARS-CoV-2 antigen test reference panels?
CLARIFIED ANSWER: The CDC's flu proficiency test panel program has served as a model for discussions on creating SARS-CoV-2 antigen test panels. It illustrates how annual panels can support rapid tests and molecular test surveillance, though SARS poses extra challenges as a biological agent.
VERBATIM QUESTION: What role does the CDC proficiency test panel program for flu play in the framework or development of SARS-CoV-2 antigen test reference panels?
VERBATIM ANSWER: On the antigen side, we've definitely had this conversation with our federal partners. It is definitely something that would be ideal to have as well. It also has its challenges so we essentially you know, to do this well and we've had a program that CDC has led for a number of years relative to flu where they make an annual proficiency test panel available for various key strains of flu for primarily for rapid antigen tests but molecular tests have also been very active in using those panels to surveil. You know, flu, when you grow a virus and you create these panels, there's less perhaps concern about this as a biological agent, flu relative to SARS so there are additional considerations for SARS but it's definitely been on the plate for conversation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CDC flu test panel, SARS-CoV-2 antigen test panels, Federal program challenges
REVIEW FLAG: False

QA Block 7-14
CLARIFIED QUESTION: Are there specific considerations for handling SARS-CoV-2 biological agents differently than other viruses like influenza in the context of developing reference panels?
CLARIFIED ANSWER: Handling SARS-CoV-2 differs from influenza due to greater concerns about SARS as a biological agent, requiring additional considerations in panel development.
VERBATIM QUESTION: Are there specific considerations for handling SARS-CoV-2 biological agents differently than other viruses like influenza in the context of developing reference panels?
VERBATIM ANSWER: You know, flu, when you grow a virus and you create these panels, there's less perhaps concern about this as a biological agent, flu relative to SARS so there are additional considerations for SARS but it's definitely been on the plate for conversation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: SARS-CoV-2 handling vs. influenza, Reference panel development
REVIEW FLAG: False

QA Block 7-15
CLARIFIED QUESTION: How will the FDA integrate international standards for molecular, antigen, and serology tests into existing regulatory frameworks and panels?
CLARIFIED ANSWER: FDA plans to anchor its reference panel to international molecular standards when available, potentially by year-end. FDA is monitoring and assisting in the development of international standards for antigen and serology tests.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: The other thing that I did want to follow-up isn't really a question about are these international standards. The reference panel that we sent out, as soon as the international standard for molecular is available and we're looking at potentially year-end, we will anchor the FDA reference panel to that and we'll be able to translate the results like we've posted to international in units. We think that will be a huge advance and on top of what we've already done. Similarly the international community is working on international standards for antigen tests and serology tests and so we're obviously monitoring and interact at table and doing what we can to assist in that development work and can be ready to implement the two worlds that become available when we do have some available so long-winded answer, great question, would be tremendous resources and all I can say is that we're doing our best to work on it right now.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: International standards, FDA reference panel, Molecular, antigen, and serology tests
REVIEW FLAG: False

QA Block 7-16
CLARIFIED QUESTION: What mechanisms are in place for developers to receive updates from the EUA review team if their assigned reviewer has not been responsive?
CLARIFIED ANSWER: Developers should receive weekly updates about their status from the EUA team. If communication is unsatisfactory, they can email the team's template mailbox for escalation to FDA leadership for further details.
VERBATIM QUESTION: What mechanisms are in place for developers to receive updates from the EUA review team if their assigned reviewer has not been responsive?
VERBATIM ANSWER: They should be able to provide you with an update at least weekly about where things stand and why you stand where you do. If they are not being transparent enough, please send an e-mail to the template's e-mail box asking it to be forwarded to me and I will look into providing you as much detail as I can on the status.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA review updates, Communication protocols
REVIEW FLAG: False

QA Block 7-17
CLARIFIED QUESTION: Can developers assist in generating or sourcing biological samples for FDA reference panels, and if so, how should they proceed?
CLARIFIED ANSWER: Developers can assist in generating or sourcing biological samples for FDA reference panels by contacting the FDA through existing communication channels. The FDA will connect them with appropriate personnel involved in setting up reference panels.
VERBATIM QUESTION: Can developers assist in generating or sourcing biological samples for FDA reference panels, and if so, how should they proceed?
VERBATIM ANSWER: Yes, you can contact me through the same means and I'll make sure that I connect you with the folks that are, you know, very closely and are involved in setting-up reference panels.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Assistance in generating reference panels, Contacting FDA for sample sourcing
REVIEW FLAG: False

QA Block 7-18
CLARIFIED QUESTION: What steps should developers follow to escalate issues or request progress updates when there are delays in the evaluation of their submissions by entities like NCI?
CLARIFIED ANSWER: FDA advises developers to request weekly updates from their assigned contact about the status of their submissions. If transparency is lacking, developers can email the template's email box to escalate the matter for further review.
VERBATIM QUESTION: What steps should developers follow to escalate issues or request progress updates when there are delays in the evaluation of their submissions by entities like NCI?
VERBATIM ANSWER: They should be able to provide you with an update at least weekly about where things stand and why you stand where you do. If they are not being transparent enough, please send an e-mail to the template's e-mail box asking it to be forwarded to me and I will look into providing you as much detail as I can on the status.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: escalation process, submission delays, progress updates
REVIEW FLAG: False

QA Block 9-10
CLARIFIED QUESTION: What steps must be completed post-market to fulfill the commitment for prospective POC studies?
CLARIFIED ANSWER: FDA requires post-market commitments for prospective POC studies to include completing the studies with prospective patients and supplementing with compatible banked samples where necessary.
VERBATIM QUESTION: What steps must be completed post-market to fulfill the commitment for prospective POC studies?
VERBATIM ANSWER: and cleared it of the template that has it in there. We have and so it's very, very similar to the molecular, there's a couple of points on both on asymptomatic and how do you finish your point-of-care studies that I do want to update you with our current thinking and it will show up in the new template updates and that is while point-of-care tests, we really want to see how it performs prospectively in the point-of-care setting. In order to speed access to point-of-care tests that haven't been previously cleared or authorized for other antigens not SARS and to get these new tests that haven't been seen before by the Agency on the market, we are allowing for you to supplement prospective patients in the point-of-care with banked samples that work with you and your technology. There is going to be a post-market, post-authorization commitment to complete the prospective portions of the point-of-care studies and there are certain ways that we want you to, you know, add those banked samples into the testing that's done in a point-of-care setting for the authorization
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Post-market POC commitments, Prospective and banked samples, FDA testing guidelines
REVIEW FLAG: False


### extract log
#### extract log header
datetime: 2025-01-03 07:18:01 UTC-08:00 America/Los_Angeles
source file prep: primary.llm.add_transcript_section_delimiters for non-FDA speakers
ROUND 1 NAME: Explicit Questions Extraction
- prompt: FCALL_SYSTEM_PROMPT_QA_QONLY_EXPLICIT_1D
- tools: tools_qa_qonly_explicit_1
- provider: openai
- model: gpt-4o-2024-11-20

#### Section 1 of 10
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 1-1: How can test developers address concerns related to false positive results for COVID-19 diagnostic tests?
QI 1-2: What steps should be taken to ensure accurate sensitivity and specificity calculations for tests in low-prevalence populations?
QI 1-3: How does the positive predictive value (PPV) change with varying population positivity rates when using high-performing tests?
QI 1-4: What guidance or tools does the FDA provide for testing positive predictive value in specific populations?
QI 1-5: What are the implications of falsely positive results on patient placement in clinical settings, such as COVID-19 wards?
QI 1-6: How can developers access and utilize the FDA SARS reference panel data for evaluating their tests?
QI 1-7: What distinctions should be noted when comparing limit of detection (LOD) across different sample types like dry swabs, saliva, and VTM?
QI 1-8: Are the methods for assessing LOD standardized across all sample types listed in the FDA SARS reference panel?
QI 1-9: When can developers expect the next batch of SARS reference panel results to be posted?
QI 1-10: What are the specific details about the methods used in assessing LOD for the FDA SARS reference panel?

#### Section 2 of 10
##### Explicit Questions Extraction
QE 2-1: Are you still updating the notification lists on your facts page regularly?

##### Implicit Questions Extraction

#### Section 3 of 10
##### Explicit Questions Extraction
QE 3-1: Do we submit one EUA and modify it or do we have to submit two EUAs?

##### Implicit Questions Extraction
QI 3-1: What are the recommended minimum criteria for sample type validation?
QI 3-2: Can updates or amendments to an EUA be submitted for additional sample types after the initial authorization?
QI 3-3: Does the FDA prioritize antigen test EUAs to expedite market availability?

#### Section 4 of 10
##### Explicit Questions Extraction
QE 4-1: What is the standard lab test against which a manufacturer should compare their at-home antigen tests?
QE 4-2: Are visually read tests excluded since there isn't a way to automatically report results to a public health agency?
QE 4-3: Why does the FDA template include a question about reporting test results to public health agencies if it is not a requirement?
QE 4-4: Is it mandatory for at-home COVID-19 tests to have a means to report results to public health agencies for FDA authorization?

##### Implicit Questions Extraction
QI 4-1: What alternative methods can be used to validate at-home COVID-19 antigen tests if the recommendations in the FDA templates are not followed?
QI 4-2: What are the sensitivity requirements for prescription-only at-home COVID-19 antigen tests?
QI 4-3: Can the sensitivity threshold for over-the-counter at-home tests be reduced if a serial testing approach is implemented?
QI 4-4: Why has the FDA not received any EUA (Emergency Use Authorization) applications for at-home tests despite publishing guidance?
QI 4-5: Is it necessary for rapid antigen or point-of-care molecular tests to demonstrate peak sensitivity during specific symptomatic days (e.g., first five to seven days after symptom onset)?
QI 4-6: How does the FDA evaluate the performance of tests for identifying asymptomatic individuals who may spread the virus?
QI 4-7: Why does the FDA avoid using LOD (Limit of Detection) as a primary metric for test validation?
QI 4-8: What are the specific criteria for the FDA to authorize visually-read COVID-19 tests?
QI 4-9: Is there a difference in how the FDA evaluates visually-read tests compared to other point-of-care tests?
QI 4-10: How can developers ensure compliance with optional reporting mechanisms suggested in the FDA template for at-home tests?

#### Section 5 of 10
##### Explicit Questions Extraction
QE 5-1: Are there any studies or results on infectivity level and viral load for symptomatic and asymptomatic individuals that can inform developers?
QE 5-2: Do you have an estimate of what is clinically relevant in terms of being infectious?

##### Implicit Questions Extraction
QI 5-1: What are the FDA's criteria for evaluating tests for asymptomatic individuals?
QI 5-2: Can asymptomatic validation involve retrospective or banked samples?
QI 5-3: Are enrichment studies an acceptable method for validating asymptomatic testing?
QI 5-4: How should developers handle residual samples collected during screenings or surveillance for asymptomatic validation?
QI 5-5: What are the FDA's expectations regarding pre-market and post-market asymptomatic data collection?
QI 5-6: Are there specific requirements for matching symptomatic and asymptomatic populations during validation?
QI 5-7: What flexibility does the FDA offer for home-use, over-the-counter tests when adding asymptomatic claims?
QI 5-8: How should developers assess the impact of different sample types on test performance in asymptomatic individuals?
QI 5-9: What risk considerations should be accounted for in non-prescription, home-use tests regarding false positives and patient interpretation?

#### Section 6 of 10
##### Explicit Questions Extraction
QE 6-1: Do we need seroconverted samples with longitudinal sampling from the day of detection to a sufficient time point for development of antibodies?
QE 6-2: Is it required to have the number of days since diagnosis for a sample when submitting data for serology tests?

##### Implicit Questions Extraction
QI 6-1: What are the specific day ranges the FDA requires test developers to evaluate for serology test performance?
QI 6-2: How should test developers handle cases where sample collection does not document the number of days since diagnosis?
QI 6-3: What is the role of line listing data in evaluating the performance of serology tests?
QI 6-4: Does the FDA adjust sensitivity requirements for IGG detection based on the number of days since symptom onset or diagnosis?
QI 6-5: Are there recommendations for addressing the waning of antibody levels when validating a test's sensitivity?

#### Section 7 of 10
##### Explicit Questions Extraction
QE 7-1: Do you have any plans for providing a reference panel for antigen test developers?
QE 7-2: Do you have any plans for providing a reference panel for serology test developers?
QE 7-3: Is there any way I can talk to you or someone else to help set up a serology reference panel?
QE 7-4: If rapid testing is offered to facilities like employers or nursing homes, is it within the limits to use those as a screening test and then perform confirmatory testing for positive results?
QE 7-5: Does a screening test for employers or nursing homes require a lab with a CLIA certificate, whether it's a waiver or otherwise?
QE 7-6: Is the test being used for screening an FDA-approved rapid test with high sensitivity?
QE 7-7: Does a low percent positive situation increase false positives even for tests with high specificity?
QE 7-8: What are the CLIA CMS regulations regarding certificates and requirements for point-of-care waived testing?

##### Implicit Questions Extraction
QI 7-1: What are the quality control and validation steps performed by the FDA to ensure consistency between reference panels for different SARS-CoV-2 tests?
QI 7-2: What challenges does the FDA face in sourcing biological samples for developing reference panels for serology and antigen tests?
QI 7-3: Is there a renewable method for creating reference panels for serology and antigen tests similar to the inactivation and growth process used for the molecular test reference panel?
QI 7-4: Can antigen test developers utilize international standards when they become available, and how will these interact with existing FDA reference panels?
QI 7-5: What role does the CDC proficiency test panel program for flu play in the framework or development of SARS-CoV-2 antigen test reference panels?
QI 7-6: Are there specific considerations for handling SARS-CoV-2 biological agents differently than other viruses like influenza in the context of developing reference panels?
QI 7-7: How will the FDA integrate international standards for molecular, antigen, and serology tests into existing regulatory frameworks and panels?
QI 7-8: What mechanisms are in place for developers to receive updates from the EUA review team if their assigned reviewer has not been responsive?
QI 7-9: Can developers assist in generating or sourcing biological samples for FDA reference panels, and if so, how should they proceed?
QI 7-10: What steps should developers follow to escalate issues or request progress updates when there are delays in the evaluation of their submissions by entities like NCI?

#### Section 8 of 10
##### Explicit Questions Extraction
QE 8-1: Could you refresh me on the name of the individual focused on software applications, data analytics, and data collection algorithms, and how she can be contacted?

##### Implicit Questions Extraction

#### Section 9 of 10
##### Explicit Questions Extraction
QE 9-1: Are there updates or specific recommendations in the antigen test template regarding point-of-care (POC) equivalent CLIA waiver studies for an EUA?
QE 9-2: Is it correct that the antigen test template suggests validating with 30 positive and 30 negative samples, and that the inclusion of asymptomatic claims is left to the developer's discretion?
QE 9-3: Can test developers mix prospective patient samples with banked samples for POC studies to expedite market access for new antigen tests?
QE 9-4: What is the FDA's stance on post-market commitments for completing prospective portions of POC studies?
QE 9-5: What should test developers provide if they wish to validate their test specifically for asymptomatic individuals?
QE 9-6: Did all antigen tests that received CLIA waivers submit POC data similar to the molecular template?
QE 9-7: What is the process for receiving current FDA feedback on point-of-care validation for antigen tests?

##### Implicit Questions Extraction
QI 9-1: Does the updated version of the antigen test template include specific recommendations for validating point-of-care (POC) tests?
QI 9-2: What guidelines should developers follow for incorporating banked samples into POC validation studies for EUA authorization?
QI 9-3: What steps must be completed post-market to fulfill the commitment for prospective POC studies?
QI 9-4: What is the FDA's position on the use of tests for asymptomatic individuals without a specific claim on the label?
QI 9-5: What data must be included if a developer wants to validate an antigen test for use in asymptomatic individuals?
QI 9-6: Where can developers find the most current version of the antigen test template?

#### Section 10 of 10
##### Explicit Questions Extraction
QE 10-1: Has anyone tried to test vaginal fluids for home test self-collection together with HPV and pap tests for a combined diagnostic model including COVID-19, HPV, and pap tests?

##### Implicit Questions Extraction
QI 10-1: What types of data are required to support the use of non-traditional sample types, like vaginal fluid, for COVID-19 testing?
QI 10-2: Why is molecular testing considered a PMA-level authorization, and what does this involve?
QI 10-3: What are the benefits and challenges of using saliva as a sample type for COVID-19 diagnostic testing?
QI 10-4: Are there specific pathways or processes that the FDA considers easier for test developers based on the type of diagnostic test?
